

A

Abscess

- Bacteremia due to, 24
- In bite wound, 95
- C. minutissimum* in, 304
- C. perfringens* in, 302
- In cellulitis, 32
- Community Associated Methicillin Resistant *Staphylococcus aureus* (CA-MRSA), 32-33
- CT scan to locate, 47
- Culture specimen from, 22-24
- In diabetic foot infections, 112
- Endocarditis prophylaxis for, 150
- In injection site, 40-41
- In osteomyelitis, 63

Absolute Neutrophil Count (ANC), 16

Acetic Acid for wound care, 86

Acid-fast smears, diagnostic

- In hematogenous osteomyelitis, 74
- In lower extremity infections, 23
- In osteomyelitis, 61

Achromobacter. See *Alcaligenes*.

Acinetobacter, 313

- Ampicillin/ sulbactam against, 241
- Ciprofloxacin, susceptibility to, 281
- Imipenem/cilastatin against, 260
- Resistant to aztreonam, 262
- Resistant to cephalosporins, 243, 245

Acinetobacter Baumannii

- Aminoglycosides against, 263
- Extremely drug resistant strains (XDR), 259
- Imipenem/cilastatin against, 259
- Resistance of, 313

Acinetobacter Iwoffii, 313

Acquired Immune Deficiency Syndrome (AIDS), 8, 208, 286

Actinomyces madurae

- Madura foot due to, 52
- Tetracyclines against, 290

Acute hematogenous osteomyelitis

See Hematogenous osteomyelitis acute.

Additive effect of drug combinations, 209

Aerobic gram-negative rods, 307-318

See also Enterobacteriaceae.

Aerobic organisms

- Aztreonam against, 262
- In bite wound infections, 95

In diabetic foot infections, 121, 123

Imipenem/cilastatin against, 259

In osteomyelitis, 77

Piperacillin/tazobactam against, 242

Tissue gas due to, 42

Aeromonas hydrophilia, 314

In marine puncture wounds, 93, 314

Vs. *Vibrio*, 314

Age

Aminoglycoside toxicity and, 264

Antibiotic selection and, 206-208

Hematogenous disease and, 72-73, 79

Surgical site infections and, 139-140

Agglutination in diagnosis of infection, 26

Agranulocytosis, 219

Air ventilation, 141

Albendazole, 53

Alcaligenes, 314

Alcohol abuse 8, 208

And agents with MTT sidechain, 221

And antibiotic selection, 208

In diagnosis of lower extremity infections, 8

And klebsiella infections, 310

Allergic reactions

Vs. anaphylactoid reaction, 221

Types of, 223-224

Allergies

And antibiotic selection, 222

In diagnosis of lower extremity infections, 7

Allylamine antifungals, 165-166

Alternative therapy

Onychomycosis and, 178

Tinea pedis and, 164

Wound care and, 86-87

Ambler Class C beta-lactamase chromosomal

Beta-lactamase combinations and, 238

Carbapenem agents resistant to, 259

Cephalosporins inactivated by, 243

American College of Chest Physicians, 14

American Diabetes Association, 103-108

American Heart Association, 150

American Medical Association (AMA) internet site, 355a

American Podiatric Medical Association (APMA) internet site, 355a

American Society for Microbiology Internet site, 355t

American Society of Anesthesiology, 134

Americans with Disabilities Act (ADA) 8, 104

- Amikacin (Amikin)
 - Daily doses of, 266, 267, 268
 - For marine puncture wounds, 93-94
 - For mycobacteria infections, 319
 - Normal blood levels, 267
- Aminoglycosides, 263-269
 - Ampicillin with, 269
 - Combination of agents using, 269
 - Dosing of, 265-268
 - Mezlocillin with, 269
 - Monitoring serum levels of, 222
 - Nephrotoxicity from use of, 215, 264
 - Neuromuscular blockade from, 214, 265
 - Open fracture infections and, 101
 - Ototoxicity from use of, 213, 265
 - Penicillin with, 209, 211, 300
 - Piperacillin with, 237
 - Risk factors for adverse reactions to, 264
 - Ticarcillin with, 237
 - Vancomycin and, 214
- Aminoglycosides, drug activity of
 - Against *E. coli* and *Klebsiella*, 309, 310
 - Against *Kingella kingae*, 305
 - Against *P. aeruginosa*, 317, 354a
 - Against *P. vulgaris* and *Providencia*, 311, 312
- Aminopenicillins, 232-234
 - List of agents in, 229t
 - Spectrum of activity by, 228-229
- Amoebae, 270
- Amorolfine (non-FDA approved), 178
- Amoxicillin, 229a, 234
 - For Lyme disease, 50
 - Against *P. multocida*, 316
 - Rash due to, 223
- Amoxicillin/clavulanic acid (Augmentin), 229t, 239-240
 - For bite wound infections, 96
 - Against cellulitis, 32
 - Against enterococci, 301
 - To fill “therapeutic holes”, 210
 - For mildly infected ulcerations, 122
 - For puncture wound infections, 92
- Ampicillin, 229t, 232-234
 - Aminoglycoside with, 269
 - Amoxicillin vs., 234
 - Against *C. diversus*, 308
 - E. coli* resistant to, 309
 - Against enterococci, 233, 301
 - H. influenzae* resistant to, 316
 - Interstitial nephritis due to, 216
 - P. mirabilis* resistant to, 233
 - Penicillins vs., 231
 - Piperacillin vs., 237
 - Platelet dysfunction due to, 220
 - Rash due to, 223
 - Seizures due to, 214
- Ampicillin/sulbactam (Unasyn), 229t, 240-241
 - Against *Acinetobacter*, 313
 - For bite wound infections, 96
 - Against cellulitis, 32
 - Against enterococci, 301
 - For infected vascular gangrene, 47
 - For moderately infected ulcerations, 125
 - Against necrotizing fasciitis, 44
 - For puncture wound infections, 92
- Amputation, limb
 - For clostridial myonecrosis, 46
 - Incidence of, 103
 - For Madura foot, 52
 - In necrotizing infections, 41
 - Rate of infection after, 131
 - Risk of ulceration and, 104
 - For synergistic necrotizing cellulitis, 45
- Anaerobic culture, 61
- Anaerobic gram-negative rods, 305-307
- Anaerobic organisms
 - In bite wound infections, 96
 - Culture and sensitivity for, 21-26
 - In diabetic foot infections, 108, 121, 123
 - Ertapenem for infections with, 261
 - Gram staining and, 21
 - Hematogenous osteomyelitis due to, 74
 - Infected vascular gangrene due to, 46
 - Injection site infections and, 40
 - In moderate to severely infected ulcerations, 123
 - Necrotizing fasciitis due to, 43
 - Secondary osteomyelitis due to, 77
 - Synergistic necrotizing cellulitis due to, 45
 - In trauma wound infections, 84t
- Anaerobic organisms (drug activity in)
 - Agents against, 269-272
 - Aminoglycosides ineffective against, 269
 - Amoxicillin/clavulanic acid against, 240
 - Ampicillin/sulbactam against, 241
 - Antianaerobic agents against, 269
 - Cefazolin against, 245
 - Cefotaxime against, 253

- Cefotetan against, 249-250
- Cefoxitin against, 249
- Cefuroxime axetil against, 251
- Clindamycin against, 269, 271
- Ertapenem vs. imipenem against, 261
- Erythromycin against some, 287
- First-generation cephalosporins against, 245
- Imipenem/cilastatin against, 259
- Metronidazole against, 269-270
- Moxifloxacin against, 284
- Penicillin against, 228, 230
- Penicillin G against, 231
- Piperacillin/tazobactam against, 41, 301
- Resistance of, to ciprofloxacin, 281
- Second-generation cephalosporins against, 245
- Tetracyclines against some, 289
- Third-generation cephalosporins against, 245
- Ticarcillin against, 236
- Ticarcillin/clavulanic acid against, 239
- Tigecycline against, 278
- Vancomycin against, 273
- Anaphylactoid reaction, 221
- Anaphylaxis reaction, 223
 - From cephalosporins, 224
 - Due to sulfonamide, 285
- Anaplasmosis (see also Lyme disease), 51
- Ancef *See* Cefazolin
- Ancylostoma brazilienses*, 53
- Anderson, J.T., 101
- Anesthesia intubation, 151
- Angiograms, 121
- Angioplasty, 127
- Animal bite wound infections. *See also specific animal.*
 - P. multocida* in, 84t, 316
 - Septic arthritis from, 94-95
 - Variables resulting in, 94-95
- Animal feed, antibiotics in, 312
- Antabuse® reaction
 - Antibiotic therapy and, 8
 - Antibiotic usage and, 220-221
 - Due to cefoperazone, 256
 - Due to metronidazole, 270
- Antacids, 282
- Antagonism effect of drug combinations, 209, 210-211
- Anthrophilic organisms, 157
- Antianaerobic agents, 269-272
- Antibiogram, 101, 140, 197, 323
- Antibiotic agents, 227-292 *See also specific agent.*
 - Bactericidal vs. bacteriostatic, 107, 201, 209, 271, 273
 - Cost of, 205
 - Dosage and administration of, 231-237, 239-242, 247-258, 260-263, 265, 270-271, 274, 276, 280, 282, 284-290
 - Drug factors of, 202-203
 - Generic and trade names of, 347a-353a
 - Killing effects of, 205-206
 - Pharmacokinetics of, 204-205
 - For prophylaxis, 148-150
 - Resistance of organisms to, 203-204
- Antibiotic breakpoints, 199-200
- Antibiotic combinations. *See also specific combinations.*
 - Contraindications for, 210-211
 - Indications for, 209-210
- Antibiotic prophylaxis, 142-153
 - Adverse effects and failures of, 153
 - After bite wound infection, 144
 - Ciprofloxacin not indicated for, 144, 150
 - Definition of, 143
 - Indications for, 144
 - Puncture wound trauma and, 144
 - Review of literature in, 142, 144, 146, 152
 - Risk of endocarditis and, 150-152
 - Rules for use of, 143
 - Selection and administration of agents for, 147-148
 - Specific antibiotics for, 148-150
 - Surgical cases indicating, 145
 - Traumatic wounds indicating, 144-145
- Antibiotic resistance, 203-204 *See also*
 - Methicillin resistance; Penicillin resistance; *specific antibiotic*; *specific organism.*
 - Aminoglycosides and, 263-264, 269
 - Anti-gram-positive antibiotics and, 272-273
 - Carbapenems, 259
 - Cephalosporins and, 243-244
 - Ciprofloxacin and, 281, 283
 - Penicillins and, 227-228
 - Prevention of, 209-210
 - Quinolones and, 280-281

- Surgical prophylaxis and, 140, 153
- Susceptibility patterns and, 196-197
- Antibiotic selection
 - Agent combination for, 209-210
 - Cost to determine. 205. *See also* Costs and cost analysis.
 - Drug activity to determine, 202-203
 - Drug of choice for, 194
 - Drug resistance to determine, 203-204
 - “Drugs for bugs” list for, 356a-357a
 - Host factors in, 206-209
 - Identity of organism for, 195-196
 - Killing effects of agent to determine, 205-206
 - Laboratory tests to determine, 197-202
 - Pharmacokinetics to determine dosage of, 204-205
 - For prophylaxis, 147-148
 - Requirements for home IV, 211-212
 - Susceptibility of organism for, 196-197
- Antibiotic serum/blood levels
 - Guidelines for determining, 267
 - Monitoring, 222, 268
- Antibiotic therapy. *See also specific agent.*
 - Arterial ulcerations and, 127-128
 - For bite wound infections, 96
 - For burn wound infections, 99-100
 - For carbuncles, 38
 - For contiguous focus osteomyelitis, 75-76
 - Culture and sensitivity during, 23-24, 60-61
 - Definition of empiric, 194
 - Diagnosis of lower extremity infections and, 6-7, 16
 - Fever of unknown origin (FUO) and, 14
 - Folliculitis, 37-38
 - For hematogenous osteomyelitis, 74
 - History of, 131
 - Home intravenous, 211
 - Impaired immune system and, 107
 - Ingress-egress drainage for, 71
 - For moderate to severely infected ulcerations, 112
 - Mycobacterium marinum* and, 94
 - Noninfected mal perforans and, 115, 117, 120
 - Open fracture infections and, 100-101
 - For osteomyelitis, 67-69
 - Paronychia and, 35
 - For post puncture wound osteomyelitis, 91, 92
 - For septic arthritis, 80
 - Stingray envenomation and, 94
 - Synergistic necrotizing cellulitis and, 45
 - Usual dosages for oral, 346a
 - Wound irrigation and, 145
- Antibiotic therapy, non-prescribed
 - In diagnosis of lower extremity Infections, 6-7
 - And injection site infections, 40-41
- Antibiotic usage
 - Allergic reactions from, 222-225
 - Monitoring blood levels during, 222, 267
 - Principles for selecting agents for, 193-212
 - Side effects from, 216-222
 - Side effects from multiple, 211
 - Side effects from prophylactic, 153
 - Toxicities from, 213-216, 264-265
- Antibiotic-associated diarrhea (AAD), 216-218
- Antibiotic-impregnated beads/fillers, 70
- Antibiotic-killing effects, 205
- Antibiotic, topical
 - For burn wound, 99
 - Against *C. minutissimum*, 204
 - For folliculitis, 37
 - Gentamicin as, 265
 - For impetigo, 39
 - For mildly infected ulcerations, 122
 - For noninfected mal perforans, 119-120
- Antibody detection, 25-26
- Antidiarrheal agents for CDAD, 217-218
- Antifungal agents, oral
 - For onychomycosis, 175-176
 - For tinea pedis, 167-168
- Antifungal agents, topical
 - Allylamines class of, 164, 166
 - Azoles class of, 166-167
 - Dosages for, 165t
 - FDA approval of, 178-179
 - Forms of, 163-164
 - Hydroxypyridone class of, 167
 - For onychomycosis, 175-176, 178-181
- Antifungal therapy
 - Discussion of oral, 181-182
 - For donor-leg cellulitis, 34
 - And lateral subungual onychomycosis, 173
 - Monitoring, 183

Pros and cons of topical, 179-181
Anti-gram positive antibiotics, 272-280. *See also specific antibiotic.*
Antihistamines
 And drug fever, 13
 And Red Man syndrome, 221
 And Vancomycin, 274
Anti-inflammatory drugs (NSAIDs), 12
Antipseudomonal penicillins, 229t
Antipyretic therapy and diagnosis of infection, 12-13
Antistreptolysin O titer (ASO), 17
Aplastic anemia, 219, 220
Aqueous penicillin, 230, 231
Arterial occlusive disease, 107
Arterial ulcerations, 126-128
Arteriosclerosis, 76
Arthralgias, 276
Arthritis
 Gouty, 30
 Migratory, 49
 Rheumatoid, 77, 78, 146
 Septic, 20, 75, 77-80, 94, 95, 232, 254, 300, 304, 305, 316, 319
Arthroscopic Examination, 80
Asepsis, 22
Aspergillus species, 170, 185
Aspirin, 12, 13
Atelectasis, 13
Athlete's foot, 156
Atypical mycobacterium, 318
Augmentin. *See* Amoxicillin/clavulanic acid.
Autonomic neuropathy, 105
Avelox *See* Moxifloxacin.
Azithromycin (Zithromax), 287-288
 Against *B. henselae*, 315
 For babesiosis, 51
 For bite wound infection, 96
 Vs. clarithromycin, 288-289
 For Erythrasma, 37
 For gonococcal infection, 304
 Against *H. influenzae*, 316
Azlocillin, 237
Azole antifungals, 166-167
Aztreonam (Azactam), 262-263
 Against *Citrobacter*, *Morganella*, *Serratia*, 308, 310, 313
 Vs. ceftaroline (non-FDA approved), 258
 Against *E. coli*, 309
 For infected vascular gangrene, 47

Against *P. vulgaris* and *Providencia*, 311, 312
And penicillin, 225
Vs. Tigecycline, 338

B

Babesiosis (see also Lyme disease) 51
 Babesia microti 50, 51
Bacteremia 13-14, 24-25, 32-33, 38, 40, 72-73, 77, 150-152, 269. *See also* Septicemia; Toxemia.
 Ecthyma with, 40
 Endocarditis prophylaxis and, 151
 Furuncle and carbuncle with, 38
 Hematogenous osteomyelitis with, 73
 Nosocomial fever with, 13
 Septic arthritis with, 77
Bacterial Pathogens. *See also specific organism.*
 In common lower extremity infections, 4, 26
 Identification of, 195-196
 Infections cause by "higher", 51-52
 List of antibiotics against, 356a-357a
 Number of, to cause infection, 22-23, 85
 Resistance patterns of, 140, 153
 In site infections, 4
 Susceptibility, 196-197
 Suspicion of anaerobic, 21
 Virulence of, 140
Bacteriologic technique for diagnosis of Infections, 19-26
Bacteroides
 In bite wound infections, 84t, 95
 In diabetic foot infections, 123
 Glycocalyx formation by, 141
 In moderate to severely infected ulcerations, 123
 Pathogenicity of, 141
 Synergistic necrotizing cellulitis due to, 45
Bacteroides, drug activity in
 Cefazolin ineffective against, 247
 Cefotaxime against, 253
 Cefotetan and, 250
 Cefoxitin against, 249
 Ceftizoxime and, 253
 Cephalosporins against, 245
 Clindamycin against, 271
 Imipenem/cilastatin against, 259
 Penicillin G and, 231

- Bacteroides asaccharolyticus *See*
 Porphyromonas asaccharolytica.
- Bacteroides fragilis*
 Amoxicillin/clavulanic acid against, 240
 Cefazolin ineffective against, 247
 Erythromycin not against, 287
 Infected vascular gangrene due to, 46
 Metronidazole against, 270
 In moderate to severely infected
 ulcerations, 123
 Ticarcillin/clavulanic acid against, 239
 Tigecycline against, 279
 In trauma wound infections, 84t
- Bacteroides melaninogenicus. See Prevotella
 melaninogenica.*
- Bacteroides thetaiotaomicron*, 305
- Bacteroides vulgatus*, 305
- Bactrim, 289-290
- Bactroban (mupirocin), 120
- Balance impairment, 265
- Bartonella henselae*, 84t, 95, 315
- Bell's palsy, 49
- Benzathine penicillin, 231
- Betadine, 231
- Beta-lactam antibiotics, 259-263
 Aminoglycosides with, 264, 269
 Effect of combining, 211
 Neutropenia due to, 219
 Platelet dysfunction due to, 219-220
- Beta-lactamase inhibitor combinations, 238-242
 Against *Alcaligenes*, 314
 Against anaerobic gram-positive cocci,
 302
 Against *Bacteroides*, 306
 Against *C. canimorsus*, 315
 Against *C. perfringens*, 303
 Vs. cefoxitin, 249
 Against *Citrobacter*, *Morganella*,
Serratia, 308, 310, 313
 Against *E.coli* and *Klebsiella*, 309, 310
 Against *E. corrodens*, 316
 Against enterococci, 301
 Against *H. influenza*, 316
 List of agents in, 229t
 Vs. metronidazole, 270
 Against *P. mirabilis*, 311
 Against *P. multocida*, 316
 Against *P. vulgaris* and *Providencia*,
 311
 Rules for use of, 238
 Spectrum of activity by, 230
- Beta-lactamase production
 Amoxicillin/clavulanic acid and, 239
 Ampicillin and, 240
 Carbapenem agents resistant to, 259
 Chromosomal. *See* Ambler Class C
 beta lactamase.
 Ciprofloxacin resistant to, 281
 By *Enterobacter*, 309
 Methicillin resistant due to, 296
 By *Morganella*, 310
 Penicillin G and, 231
 Penicillins' actions and, 228
 By *Serratia*, 313
 Third-generation cephalosporins and,
 245
 Ticarcillin and, 236
 Ticarcillin/clavulanic acid and, 239
- Beta-lactam/beta-lactamase inhibitor compounds
 For bite wound infections, 96
 For moderate to severely infected
 ulcerations, 125
 Resistance to, 204
- Betamethasone dipropionate and clotrimazole
 (Lotrisone), 165t, 166
- Bifonazole (non-FDA approved), 178
- Biliary elimination
 Of cefoperazone, 256
 Of ceftriaxone, 254
- Bioavailability, drug, 204
- Biopsy, skin
 Of cutaneous larva migrans (CLM), 52
 For diagnosis of Lyme disease, 49
 Following burn trauma, 98
- Bite wound infections
 Amoxicillin/clavulanic acid for, 240
 Anaerobic gram-negative rods in, 306
 Antibiotic prophylaxis preventing, 144-
 145
B. henselae in, 315
C. canimorsus in, 315
 Clinical presentation of, 95
E. corrodens, 315
 Laboratory findings and etiology of, 95
 Organisms causing, 84t
P. multocida in, 316
 Pet owners and, 8
 Piperacillin/tazobactam for, 242
 Septic arthritis due to, 78, 94
 Ticarcillin/clavulanic acid for, 239
 Treatment for, 96
 Variables resulting in, 94-95

- Bleeding
 - Due to antibiotic usage, 219-220
 - Due to cefoperazone, 256
 - Due to cefotetan, 250
 - Due to cephalosporins, 246
 - Due to penicillins, 230
 - Due to ticarcillin, 236
 - Blood
 - As alternative therapy for wound care, 86
 - With infection drainage vs. hematoma, 134-135
 - Salmonella* in, 312
 - V. vulnificus* in, 318
 - Blood chemistry in diagnosis of infection, 17-18
 - Blood culture, 24-25
 - For cellulitis, 31-32
 - For contiguous focus osteomyelitis, 75
 - For ecthyma, 40
 - For hematogenous osteomyelitis, 73
 - For Lyme disease, 49
 - For moderate to severely infected ulcerations, 123
 - For necrotizing fasciitis, 43
 - For nosocomial fever, 13
 - For osteomyelitis, 60
 - For scalded skin syndrome, 38
 - For septic arthritis, 79
 - For synergistic necrotizing cellulitis, 44
 - Blood urea nitrogen (BUN) levels
 - In diagnosis of lower extremity infections, 18
 - In moderate to severely infected ulcerations, 123
 - Bloodborne Pathogen link on OSHA Internet site, 355a
 - Body fluid discoloration, 280
 - Body response to site infections, 3-4
 - Bone biopsy
 - In Charcot joint, 107
 - In osteomyelitis, 60
 - Bone culture
 - Contamination of, 61, 68
 - In diagnosis of bone and joint infections, 60-62
 - Of hematogenous osteomyelitis, 73
 - Of moderately infected ulcerations, 123
 - After puncture wound trauma, 91
 - Bone fractures and osteomyelitis (CFO), 75
 - Bone graft, 71
 - Bone infections, 55-81
 - Ceftazidime for, 255
 - P. aeruginosa* in, 317
 - Bone penetration studies in osteomyelitis, 68-69
 - Bone scans, 63-65, 67, 75, 91, 106
 - Bones, staining of, 290
 - Borrelia Burgdorferi*
 - Lyme disease due to, 48, 49
 - Septic arthritis due to, 80
 - Tetracyclines against, 290
 - Travelers infected with, 9
 - Brodie's abscess, 63
 - Broth tube dilution technique, 198
 - Brotzu, G., 242
 - Brucella*, 26
 - Bullae, 7, 38, 42, 45
 - Burgdorfer, W., 48
 - Burke, 143
 - Burkholderia cepacia*, 317-318
 - Resistant to aztreonam, 262
 - Resistant to ciprofloxacin, 281
 - Trimethoprim/sulfamethoxazole against, 285, 286
 - Burn centers, 99
 - Burn wound infections
 - Bacterial etiology, 98-99
 - Classification of, 97-98
 - Clinical signs of, 97-98
 - Factors leading to, 97
 - Laboratory findings of, 98
 - Organisms causing, 84t
 - Topical agents for, 99
 - Treatment for, 99-100
 - Butenafine (Mentax), 164, 165t
- C**
- Caffeine with antibiotic usage, 282
 - Calf muscles, pyomyositis in, 47
 - Calf tenderness, 34
 - Cancellous bone graft, 71
 - Candida* 35, 157, 161, 170, 185
 - Itraconazole (Sporanox), 185
 - Onychomycosis and, 170
 - Paronychia due to, 35
 - Resistance of, 161
 - Candida albicans*, 157
 - Candida parapsilosis*, 157
 - Capnocytophaga canimorsus*, 315
 - Carbacephem, 252
 - Carbapenem antibiotics, 259-262
 - Against *Alcaligenes*, 314

- Against *Bacteroides*, 306
- Against *Citrobacter*, *Morganella*,
Serratia, 308, 310, 313
- Against *E.coli* and *Klebsiella*, 309, 310
- Against *P. vulgaris* and *Providencia*,
311, 312
- Against *S. maltophilia* and *B. cepacia*,
318
- Carbenicillin, 229t, 236
- Carboxypenicillins, 229t
- Carbuncles, 38, 329
- Carcinogenic effects, 270
- Cartilage degeneration, 282
- Casting, wound care, 119, 124
- Cat bite wound infection
 - B. henselae* in, 95, 315
 - Organisms causing, 84t
 - P. multocida* in, 316
 - Septic arthritis from, 80
 - Variables resulting in, 94-95
- Cat parasites, 53
- Cat scratch disease, 84t, 315
- Catheters, nosocomial fever with indwelling, 13
- Cedax (ceftibuten), 257
- Cefaclor (ceclor), 244t, 251, 252
- Cefadroxil (duricef), 244t, 248
- Cefazolin (Ancef, Kefzol), 244t, 246-247
 - For cellulitis, 32
 - For open fracture infections, 101
 - For necrotizing fasciitis, 44
 - For puncture wound infections, 92
 - For pyomyositis, 47
 - For scalded skin syndrome, 38
 - For surgical prophylaxis, 148-149
- Cefdinir (Omnicef), 244t, 256-257
- Cefepime (Maxipime), 93, 244t, 257-258
- Cefixime (Suprax), 257
- Cefoperazone (Cefobid), 244t, 255-256
- Cefotaxime (Claforan), 244t, 252-253
 - Vs. cefoperazone, 255
 - Vs. ceftizoxime, 253
 - Against *V. vulnificus*, 318
- Cefotetan (Cefotan), 244t, 249-250
 - Against *Bacteroides*, 306
- Cefoxitin (Mefoxin)
 - Against *Bacteroides*
 - For moderately infected ulcerations, 125
 - For mycobacteria infections, 319
- Cefpodoxime proxetil (Vantin), 257
- Cefprozil (Cefzil), 244t, 252
- Ceftaroline, 339
- Ceftazidime (Fortaz, Tazicef, Tazidime)
 - Against *B. cepacia*, 318
 - Vs. cefepime, 258
 - Vs. cefoperazone, 255, 256
 - Vs. cefotaxime, 255
 - Vs. ceftobiprole, 258, 339
 - For post-puncture-wound osteomyelitis,
93
 - Against *V. vulnificus*, 318
- Ceftibuten (Cedax), 257
- Ceftizoxime (Cefizox), 244t, 253-254
- Ceftriaxone (Rocephin), 244t, 254-255
 - For gonococcal infection, 304
 - For *Kingella kingae* infection, 305
 - For Lyme disease, 50
 - For surgical prophylaxis, 149
 - For systemic *N. meningitidis* infection,
305
- Cefuroxime axetil (Ceftin), 244t, 251-252
 - For bite wound infection, 96
 - Vs. cefprozil, 252
 - For Lyme disease, 50
- Cefuroxime (Zinacef), 149, 244t, 250-251, 297
- Cellulitis, 9-10, 31-32 *See also* donor-leg
cellulitis; synergistic necrotizing
cellulitis.
 - After bite wound trauma, 95
 - With burn wound, 98
 - Cardinal signs of, 9-10
 - Clinical presentation of, 31
 - Conditions mimicking, 10
 - Culture from site of, 24
 - In diagnosis of lower extremity
infections, 9-10
 - Documenting, 10
 - Due to *S. aureus*, 296
 - Erysipelas form of, 41
 - H. influenzae* in, 316
 - With impetigo, 39
 - With injection site abscess, 40
 - In mildly infected ulcerations, 121
 - In moderate to severely infected
ulcerations, 123
 - With necrotizing fasciitis, 42, 43
 - With paronychia, 34
 - Penicillin G for superficial, 232
 - With puncture wounds, 84t, 91
 - Treatment for, 32
- Celsus, five cardinal signs, 9-10
- Centers for Disease Control and Prevention
Internet site for, 355a

- Wound classification by, 134
- Central fever, 13
- Cephalexin (Keflex, Keftab), 244t, 248
 - Vs. cefdinir, 256
 - For cellulitis, 32
 - For mildly infected ulcerations, 122
 - For puncture wound infections, 92
 - Surgery and, 331
- Cephalosporins, 242-258
 - First-generation agents of, 244t, 245, 246-248
 - Second-generation agents of, 244t, 245, 248-252
 - Third-generation agents of, 244t, 245, 252-257
 - Fourth-generation agents of, 244t, 245, 257-258
 - Fifth-generation agents of, 246, 258
 - Adverse reactions to, 246
 - Ciprofloxacin vs., 283
 - Classification of, 243-245
 - Dosages of, 346a
 - History of, 242
 - List of agents in, 244t
- Cephalosporins, drug activity of
 - Aeromonas* resistant to, 314
 - Against *Alcaligenes*, 314
 - Bacteroides* resistant to, 306
 - Against *C. canimorsus*, 315
 - Against *C. perfringens*, 303
 - Against *Citrobacter*, *Morganella*, *Serratia*, 308, 310, 313
 - Against *E. coli* and *Klebsiella*, 309, 310
 - Against *E. corrodens*, 316
 - Against *H. influenzae*, 316
 - Against *Kingella kingae*, 311
 - Against *P. mirabilis*, 311
 - Against *P. multocida*, 316
 - Against *P. vulgaris* and *Providencia*, 311, 312
 - Resistance to, 296
 - Against *S. aureus*, 296
 - S. maltophilia* and *B. cepacia* resistant to, 318
 - Against *Salmonella*, 312
 - And streptococci sensitivity, 300
- Cephalosporins, therapy with
 - For bite wound infections, 96
 - CDAD due to, 217
 - For endocarditis prophylaxis, 151
 - For gonococcal infections, 304
 - Hematologic reactions due to, 220
 - For impetigo, 39
 - For infected vascular gangrene, 47
 - For marine puncture wounds, 93
 - Nephrotoxicity due to, 216
 - Neutropenia due to, 219
 - And open fracture infections, 101
 - And penicillin, 224-225
 - During pregnancy, 208
- Cephamycin, 248, 249
- Cerebrospinal fluid (CSF) and Lyme disease, 49
- Charcot joint
 - Cellulitis vs., 10
 - Etiology of, 106
 - Osteomyelitis vs, 63, 66, 106
- Chemical debridement, 85-87, 127
- Chemotactic cascade, 4, 10
- Chemotaxis, 10, 97, 107-108, 139
- Chemotherapy, 16
- Children
 - Antibiotic selection, 207
 - Ciprofloxacin and, 282
 - Ecthyma and, 39
 - H. influenzae* in, 316
 - Hematogenous osteomyelitis in, 207
 - Kingella kingae* infections in, 305
 - Scalded skin syndrome and, 38
 - Septic arthritis in, 79
- Chloramphenicol, 275
 - Hematologic reactions due to, 219, 220
 - In hepatic dysfunction, 208
- Chronic indurated cellulitis, 10
- Ciclopirox (Ioprox)
 - For distal subungual onychomycosis (DSO), 172
 - For tinea pedis, 167
- Ciclopirox nail lacquer (Penlac), 179
 - AN2690 vs., 180-181
 - For onychomycosis, 172
 - Pros and cons of, 179-180
- Cierny, G., 56
- Cilastatin, 259
- Ciprofloxacin (Cipro), 281-283
 - Vs. cefepime, 258
 - Contraindications for use of, 283
 - For diabetic foot infections, 283
 - Dosage of, 346a
 - For injection site infections, 41
 - Vs. levofloxacin, 283, 284
 - For marine puncture wounds, 93
 - Vs. moxifloxacin, 284

- For necrotizing fasciitis, 44
- For osteomyelitis, 93
- And rifampin, 281
- S. maltophilia* and *C. cepacia* resistant to, 318
- For surgical prophylaxis, 150
- Against *V. vulnificus*, 318
- Circulatory problems
 - Antibiotic selection and, 209
 - Antibiotics in patients with, 69
 - Paronychia with, 36
- Citrobacter*, 308
 - Beta-lactamase by, 238
 - Ciprofloxacin against, 281
 - Diversus* species of, 308
 - Freundii* species of, 308
- Clarithromycin (Biaxin), 288-289
 - Vs. azithromycin, 288, 289
 - Against *B. henselae*, 315
 - For erythrasma, 37
 - Against *H. influenzae*, 316
 - Against *M. marinum*, 319
 - For marine puncture wounds, 94
 - For mycobacteria infections, 319
- Clindamycin (Cleocin), 271-272
 - With aztreonam, 263
 - For babesiosis, 51
 - CDAD due to, 217
 - With cefotaxime, 253
 - For cellulitis, 32
 - With ciprofloxacin, 283
 - For clostridial myonecrosis, 46
 - Dosage of, 346a
 - For ecthyma, 40
 - For erythrasma, 37
 - For folliculitis, 38
 - In hepatic dysfunction, 208
 - For impetigo, 39
 - For infected vascular gangrene, 47
 - For mildly infected ulcerations, 122
 - For moderate to severely infected ulcerations, 125
 - For necrotizing fasciitis, 44
 - For osteomyelitis, 69
 - For puncture wound infections, 92
 - For pyomyositis, 48
 - For surgical prophylaxis, 149
 - With ticarcillin, 237
- Clindamycin (Cleocin), drug activity
 - Against anaerobic gram positive cocci, 302
 - Against *Bacteroides*, 306
 - Against beta-hemolytic streptococci, 299
 - Against *C. canimorsus*, 315
 - Against *C. minutissimum*, 304
 - Against *C. perfringens*, 303
 - Against *S. aureus*, 297
- Clindamycin solution, 37
- Clinical diagnosis *See also specific infection.*
 - Bacteriologic techniques for, 19-26
 - Common organisms in, 26
 - Definition of infection for, 3-4
 - Etiologies in, 4-5
 - Hospitalization and, 26-28
 - Laboratory tests for, 15-18
 - Patient history in, 4-9
 - Physical examination in, 9-14
- Clinical Infectious Diseases*, electronic edition, 355a
- Clinical Laboratories Standards Institute (CLSI)
 - Drug breakpoints established by, 200
 - Sensitivity testing standards by, 161
 - Zone-of-inhibition standards by, 197
- Clostridia
 - Appearance of, 20t
 - Clindamycin moderately against, 271
 - Imipenem/cilastatin against, 259
 - Penicillin G and, 231
 - Vancomycin against, 273
- Clostridial myonecrosis, 45-46, 302
- Clostridium difficile*
 - Cephalosporins ineffective against, 246
 - Clindamycin ineffective against, 271
 - Imipenem/cilastatin ineffective against, 259
 - Metronidazole against, 271
- Clostridium difficile*-associated diarrhea (CDAD), 216-218
- Clostridium difficile* colitis, 271, 274, 275, 335
- Clostridium perfringens*, 302-303
 - Clostridial myonecrosis due to, 45
 - Infections with, 6
 - Tissue gas and, 42
- Clostridium tetani*, 302
- Clotrimazole (Lotrimin AF), 165t, 166
- Cloxacillin, 32, 229t, 235
- CMS (Centers for Medicare & Medicaid Services), 27, 145, 341
- Cockcroft and Gault formula, 17, 266
- “Cold steel” debridement, 128
- Colistin, 290

- Colitis. *See Clostridium difficile* colitis.
- Community associated MRSA, *see* MRSA, community associated.
- Complete bed rest, 27
- Complete blood count (CBC) with differential, 15, 188
- Compresses, warm. *See also* Soaks, foot.
- Computed tomography, 66
- “Concentration-dependent killing”, 205, 206, 268
- Congenital abnormalities onychomycosis, 173
- Connective tissue toxicity, 282
- Contact lenses, discoloration of, 280
- Contamination, *See also* Fecal contamination
- Asepsis to lessen, 22
 - Of blood cultures, 25
 - Of burn wound, 99
 - By *Corynebacterium*, 303
 - By enterococci, 300
 - Of fish tanks, 319
 - Vs. infection, 20
 - By mycobacteria, 319
 - Of nail cultures, 170
 - And noninfected mal perforans, 115, 117-118
 - With *P. aeruginosa*, 317
 - With *Proteus*, 311
 - Of raw oysters, 318
 - Of surgical site, 132-133
- Contiguous-focus osteomyelitis (CFO), 55, 74-75
- Continuous bacteremia, 25
- Continuous fever, 12
- Corticosteroids, 62, 77, 146, 167, 208
- Corynebacteria, 273
- Corynebacterium jeikeium*, 303
- Corynebacterium minutissimum*, 37, 303-304
- Corynebacterium* organism
- Appearance of, 20t
 - Contamination by, 25
 - Diphtheroids in, 303
- Cost and cost analysis
- Of aminoglycoside usage, 269
 - Of amoxicillin/clavulanic acid, 240
 - Of antibiotic selection, 194, 205
 - Of cefazolin vs. penicillin, 247
 - Of ceftriaxone, 149, 255
 - Of cefuroxime vs. others in class, 251
 - Of cephalexin, 248
 - Of cloxacillin and dicloxacillin, 235
 - Of combining antibiotics, 211
 - Of imipenem/cilastatin, 259, 260
 - Of linezolid, 277
 - Of metronidazole, 270
 - Of nafcillin, 235
 - Of onychomycosis, 169
 - Of oral antifungals, 182
 - Of piperacillin/tazobactam, 242
 - Of postoperative infections, 132
 - Of quinupristin/dalfopristin, 276
 - Of surgical site infections, 131
 - Of Vancomycin, 273, 275
- C-reactive protein, 16, 59, 108
- Creatinine clearance
- Aminoglycosides dosage and, 266
 - Ampicillin dosage and, 233
 - Cefotaxime dosage and, 253
 - Equation for calculating, 17, 266
 - Normal, defined, 266-267
 - Penicillin G dosage, 231
 - Piperacillin/tazobactam dosage and, 241
 - Ticarcillin dosage and, 236
- Creatinine levels, serum
- In diagnosis of lower extremity infections, 17
 - In moderate to severely infected ulcerations, 123
 - “Creeping eruption”, 52
 - “Crossover allergy”, 224
- Cross-reactivity, 224-225
- Between aminoglycosides and loop diuretics, 264
 - Between aztreonam and penicillins or cephalosporins, 263
 - Between cephalosporins and beta-lactams, 246
 - Between imipenem and penicillin, 260
- Crystalluria and sulfonamide usage, 286
- Culture and sensitivity
- And arterial ulcerations, 127
 - Of bite wound, 96
 - Of burn wound, 99
 - Of cellulitis exudate, 31-32
 - And contiguous focus osteomyelitis, 74
 - Of *Corynebacterium* infection, 303
 - For detection of VISA, 296
 - And diagnosis of lower extremity infections, 21-22
 - And diagnosis of Lyme disease, 49
 - Of erythrasma, 37
 - Of folliculitis, 37
 - Of impetigo, 39

- Of mildly infected ulcerations, 121
- And paronychia, 35
- After puncture wound trauma, 91
- And septic arthritis, 79
- “Therapeutic holes” in, 210
- For wound closure, 87
- Culture and sensitivity technique
 - Absence of exudate for, 24, 31-32
 - Amount of specimen for, 22
 - Broth tube dilution method of, 198-199
 - Collecting specimen for, 22, 194-195
 - Collection site, 21-22
 - Disc-diffusion method, 197-198
 - Order of specimens for, 23
 - Time required for report of, 196
 - Transportation of specimens for, 23
- Culture for *C. difficile*, 217
- Cutaneous larva migrans (CLM), 9, 52-53
- Cytochrome P450 isoenzyme 3A4, 186, 289
- Cytomegalovirus (CMV), 223, 233

D

- Dakin’s solution (sodium hypochlorite), 120
- Daptomycin, 126, 273
- Daptomycin against VISA, 297
- Darier’s disease, 173
- Deafness due to antibiotic usage, 213
- Debilitated patients, *Enterobacter* infection in, 308
- Debridement 22, 27, 42-46, 55, 58, 60, 66-72, 74-77, 85-88, 93,96, 99-100, 112, 117-119, 121, 127, 136, 145, 169, 172,175-177, 179-180, 189, 212, 303, 319, *See* “Cold steel”.
 - For onychomycosis 176-177
- Decompression for clostridial myonecrosis, 46
- Deep vein thrombophlebitis (DVT), 7, 10
- DEET for prevention of Lyme disease, 50
- Dental procedures after joint implants, 152
- Dermatological reactions, 221, 223
- Dermatophyte test media (DTM), 160
- Dermatophytes
 - Infections due to, 128
 - Onychomycosis due to, 170
 - Tinea pedis due to, 156-157
- Dermatophytosis complex/simplex tinea pedis, 159
- Desacetyl cefotaxime, 253
- Devastating results, antibiotic prophylaxis and, 146

- Devitalized tissue
 - In bite wound infections, 95
 - Infections following trauma, 82
- Diabetes mellitus
 - Antibiotic selection and, 207, 208
 - Enterobacter* infection in, 308
 - Hospitalization for, 27
 - Infected vascular gangrene in, 46
 - MRI differentiation of, 66
 - Onychomycosis in, 169
 - Osteomyelitis in, 59
 - Osteomyelitis secondary to, 76
 - Site infections with, 7
 - Surgical prophylaxis for, 146
 - Synergistic necrotizing cellulitis in, 44
 - Triple-agent combinations and, 269
- Diabetic angiopathy, 107-108
- Diabetic foot infections, 103-130
 - Anaerobic gram-negative rods in, 306
 - Anaerobic gram-positive cocci in, 296
 - Bacteroides* in, 306
 - Beta-hemolytic streptococci in, 299
 - Microbiology of, 110-113
 - Miscellaneous infections in, 128
 - MRSA causing, 329
 - Pathogenesis of, 104-110
 - S.aureus* major cause of, 296
 - Statistical data about, 103-104
 - Streptococci in, 299
 - Ulceration in, 113-128
- Diabetic foot infections, treatment of
 - Amoxicillin/clavulanic acid for, 240
 - Ampicillin/sulbactam for, 241
 - Cefotaxime for, 253
 - Cefoxitin for, 249
 - Cefoxitin vs. beta-lactamase inhibitors for, 249
 - Ceftibiprole (non-FDA approved) and, 339
 - Ciprofloxacin plus other drugs for, 283
 - Clindamycin and quinolone for, 272
 - Linezolid for, 277
 - Daptomycin for, 338
 - Ertapenem vs. piperacillin/tactobactam for, 261-262
 - Home IV antibiotic therapy for, 212
 - Imipenem/ cilastatin for, 260
 - Levofloxacin for, 284
 - Metronidazole plus other drugs, 270
 - Moxifloxacin and, 284
 - Piperacillin/tactobactam for, 242

Ticarcillin/clavulanic acid for, 239
Triple-agent combinations for, 269
Diabetic Immunopathy, 107
Diabetic neuroarthropathy, *See* Charcot joint.
Diabetic neuropathy, 104-107
Diabetic ulceration, 75, 272
Diagnosis of lower extremity infections. *See*
clinical diagnosis.
Diagnosis-related groups (DRGs), 211
Dialysis, 215, 275
Diarrhea
Due to amoxicillin/clavulanic acid, 240
Due to ampicillin, 233
Due to antibiotic usage, 216-218
Due to cefoperazone, 256
Due to cephalosporins, 246
Due to ceftriaxone, 254
Due to clindamycin, 271
Due to penicillin, 230
Dicloxacillin, 229t, 235
For cellulitis, 32
For impetigo, 39
Vs. methicillin, 325
Diflucan (fluconazole), 184-185
Digital plethysmography, 127
Diphtheroids, 87, 303
Direct extension osteomyelitis. *See* Contiguous-
focus osteomyelitis (CFO).
Direct extension septic arthritis, 78, 80
Disc-diffusion method, 197-198, 199
Discharge planning, 211
“Dishwater” pus, 44
Disinfectants, topical, 119-120
Disseminated gonococcal infection (DGI), 304
Distal subungual onychomycosis (DSO), 170-
171, 172
Disulfiram-like reaction, *see* Antabuse reaction
Dizziness. *See* Vertigo.
Dog bite wound infections
 C. canimorsus causing, 315
 Organisms causing, 84t
 Variables resulting in, 94-95
Dog hookworm, 53
Donor-leg cellulitis, 33-34
Doripenem (Doribax), 262
Dorsal space infections, 128
Dosing nomogram, 17, 267
Dosing schedules
 Aminoglycosides and, 263
 Cefadroxil and, 248

Creatinine clearance equation for, 17,
266
Daptomycin and, 278
Of oral antifungals, 182
Types of, 266-268
Doxycycline, 289-290
For anaplasmosis, 51
Against *B. henselae*, 315
For CA-MRSA, 33, 328, 333
Against *C. canimorsus*, 315
Dosage of, 290
Against *E. corrodens*, 316
For Lyme disease, 50
Against *M. marinum*, 319
For MRSA, 297
Against mycobacteria, 319
Against *P. multocida*, 316
For prevention of Lyme disease, 50
Against *S. maltophilia* and *B. cepacia*,
318
Against *V. vulnificus*, 318

Drake, Lynn, 169
Drug fever, 13, 224
“Drugs for Bugs” list, 356a-357a
Dry mouth, 270
D-Test, 334
Duricef (cefadroxil), 244t, 248
Dye, *Serratia* in marker, 312
Dysgonic Fermenter-2 (DF-2), *See*
Capnocytophaga canimorsus.
Dystrophic nail. *See* Onychomycosis.

E

Ear disorders. *See* Ototoxicity.
Ecchymosis, 42, 94, 305
Econazole (Spectazole), 165t, 166-167
Ecthyma, 39-40
Ecthyma gangrenosum, 40
Edema
In autonomic neuropathy, 105
In cellulitis, 10, 31
In hematoma vs. infection, 134
And immediate hypersensitivity, 223
In Madura foot, 52
In mildly infected ulcerations, 121
In necrotizing infection, 42
In osteomyelitis, 76
In paronychia, 34
In puncture wound, 91
In pyomyositis, 47
In septic arthritis, 78

- In synergistic necrotizing cellulitis, 44
- Educated guess
 - In antibiotic selection, 195
 - In diagnosis of lower extremity infections, 26
- Eikenella corrodens*, 84t, 315-316
- Elderly
 - And antibiotic selection, 206-207
 - With hematogenous osteomyelitis, 72, 73
 - With osteomyelitis, 57
 - With septic arthritis, 79
 - With surgical site infections, 139-140
- Electrolytes
 - In diagnosis of lower extremity infections, 18
 - Imbalances of, due to penicillin, 230
- Endocarditis
 - Bacteremia and, 24
 - Burn wounds and, 97
 - Home IV antibiotic therapy for, 211
 - Surgical prophylaxis for, 150-153
 - Viridans streptococci causing, 300
- Endogenous pyrogen, 11
- Enterobacter*, 308-309
 - Beta-lactamase by, 238
 - Ciprofloxacin against, 264
 - In diabetic foot infections, 123
 - In moderate to severely infected ulcerations, 123
- Enterobacter cloacae*, 308, 309
- Enterobacteriaceae, 307-313
 - Cefdinir and, 256
 - Cefepime against, 258
 - Cefpodoxime proxetil against, 257
 - Drug resistance of, 204, 272
 - Ertapenem vs. imipenem against, 261
 - Infected vascular gangrene due to, 46
 - Ticarcillin against, 236
 - In trauma wound infections, 84t
- Enterococci, 300-301
 - Aminoglycosides/beta-lactam against, 264, 269
 - Amoxicillin/clavulanic acid against, 240
 - Ampicillin against, 233
 - Ampicillin/sulbactam against, 240
 - Cephalosporins ineffective against, 246
 - Clindamycin ineffective against, 271
 - Erythromycin not against, 287
 - Imipenem/ cilastatin and, 259
 - Mezlocillin against, 269
 - Nafcillin ineffective against, 234
 - Penicillin G and, 231
 - Tetracyclines not against, 289
 - Ticarcillin and, 236
 - Trimethoprim/sulfamethoxazole not against, 285
 - Vancomycin against, 273
- Enterococcus*
 - Ampicillin against, 234
 - Cefoxitin and, 249
 - Ciprofloxacin and, 265
 - Linezolid and, 276
 - Penicillin and aminoglycosides against, 209
 - Piperacillin/ tazobactam against, 241
 - Quinupristin/ dalfopristin against, 276
- Enterococcus faecalis*, 300
- Enterococcus faecium*, 276, 300
- Enterococcus*, Vancomycin-resistant (VRE), 273, 301, 307
 - Antibiotics for infection with, 301
 - Daptomycin and, 278
 - Linezolid against, 276
 - Quinupristin/ dalfopristin against, 275-276
- Enzyme-linked immunosorbent assay (ELISA)
 - In diagnosis of CDAD, 217
 - In diagnosis of lower extremity infections, 17
 - And diagnosis of Lyme disease, 49
- Eosinophilia, 15, 53
- Epidermophyton floccosum*, 157
- Epstein-Barr 223, 233
- Ertapenem (Invanz), 261-262
- Erysipelas, 41, 299
- Erythema
 - In burn wound infections, 97
 - In cellulitis, 10
 - In contiguous focus osteomyelitis, 75
 - In ecthyma, 30
 - In hematoma vs. infection, 134
 - In mildly infected ulcerations, 121
 - In necrotizing fasciitis, 42, 43
 - In paronychia, 34
 - In pyomyositis, 47
 - In Red Man Syndrome, 221
 - In septic arthritis, 78
- Erythema migrans (EM) 48-51, 80, 290, *See also* Lyme disease.
- Erythrasma, 36-37, 303

Erythrocyte sedimentation rate (ESR)
 In contiguous focus osteomyelitis, 75
 In diagnosis of lower extremity infections, 16
 In hematogenous osteomyelitis, 73
 In moderate to severely infected ulcerations, 123
 In osteomyelitis, 59
 In paronychia, 34-35
 In puncture wound infections, 91
 In pyomyositis, 47

Erythromycin, 286-287
 Against *C. minutissimum*, 304
 Dosage of, 288
 D-Test and, 334
 For Erythrasma, 37
 GI side effects due to, 218
 In hepatic dysfunction, 208
 Hepatotoxicity due to, 216
 For impetigo, 39
 Ototoxicity due to, 213-214
 During pregnancy, 208
 Resistance and, 299, 303, 315

Escherichia coli, 309
 And ampicillin, 233
 Aminopenicillins against, 229
 Azithromycin against, 288
 Cefazolin against, 247
 Cephalosporins against, 243, 245
 Drug resistance of, 204
 In moderate to severely infected ulcerations, 123
 Ticarcillin/ clavulanic acid against, 239
 In trauma wound infections, 84t

Eumycetoma, 52

Exelderm (sulconazole), 165t, 167

Exfoliative dermatitis, 221

Exogenous pyrogen, 11-12

Extended spectrum beta-lactamase (ESBL)
 Amoxicillin/clavulanic acid against organisms with, 240
 Carbapenem against, 259
 Cefotaxime and, 253
 Cephalosporin resistance and, 243, 245
 Enterobacteriaceae resistance and, 307-308
 Penicillins and, 299, 230
Salmonella resistance and, 312

External fixation devices, 71-72

Exudate
 Absence of, culture, 24

Absence of, in cellulitis, 30-31
 In burn wound infections, 97
 In clostridial myonecrosis, 45
 In hematoma vs. infection, 134-135
 In impetigo, 39
 In infected vascular gangrene, 46
 In mildly infected ulcerations, 121
 In moderate to severely infected ulcerations, 124
 In necrotizing fasciitis, 43
 In paronychia, 34
 In pyomyositis, 47
 In synergistic necrotizing cellulitis, 44
 In tinea pedis, 159
 And wound closure, 87

F

Face masks and surgical site infections, 141

Facultative bacteria, 42, 45

Fecal contamination, 133
 “Fecal fallout”, 309

Fetid foot, 124

Fever, 11-14
 Antipyretic therapy, 12-13
 Body’s response of, 11-12
 Curves, 12
 In diagnosis of lower extremity infections, 5
 In hematogenous osteomyelitis, 73
 Hospitalization for, 27
 In severely infected ulcerations, 126
 Nosocomial, 13
 Pyrogens, 11-12
 In sepsis, 14
 In septic arthritis, 78
 Types of, 12-14
 Of unknown origin, 13-14

Fever curves
 During antipyretic therapy, 12
 In diagnosis of lower extremity infections, 12
 During hospitalization, 27

Fever of unknown origin (FUO)
 Blood culture in, 25
 Determining etiology of, 13-14

Fish, puncture wounds, 318

Fish tank organisms, 319

Flagyl. *See* Metronidazole.

Fleming, A., 227, 324
 “Flesh-eating bacteria”, 299, 324

Florey, H.W., 227, 324

- Floxin. *See* Ofloxacin.
- Fluconazole (Diflucan), 184-185
- Fluid retention, 236, 239
- Fluid/electrolyte therapy
 For Antabuse reaction, 221
 For CDAD, 217
 For scalded skin syndrome, 38
- Flu-like symptoms, 280
- Flushing, 71, 220, 221, 274
- Folliculitis, 37-38
- Food and Drug Administration (FDA)
 Approval of antifungals by, 155
 On fluconazole (Diflucan), 184-185
 On itraconazole (Sporanox), 185-186
 On oral antifungals, 176-177, 181
 New FDA approvals, 124-125
 And papain removal, 86
 And Pexiganan, 122
 On pulse dosing, 182
 On quinolones, 280, 282
 Reports of deaths by, 181, 183
 On terbinafine (Lamisil), 183, 187-188
 On topical antifungals, 178-179
- Food intake
 And amoxicillin serum levels, 234
 And amoxicillin/ clavulanic acid, 240
 And cloxacillin and dicloxacillin, 235
- Foot flora, 311
- “Foot infection”, 156
- Foreign substances/ bodies
 Infections following surgery, 133
 Infections following trauma, 83, 85
 In puncture wound infections, 89, 92
- Fortaz (ceftazidime), 244t, 255
- Fractures, infections of open
 Antibiotic therapy for, 100-101
 Debridement for, 100
 Fixation for, 101
 Organisms causing, 84t
- Frostbite, osteomyelitis secondary to, 76
- Fruits, contaminated, 317
- Fulvicin (griseofulvin)
 History of, 155, 175, 181
 For onychomycosis, 183-184
 For tinea pedis, 167-168
- Fungal cultures
 From bone culture, 61
 Contamination of, 160
 In diagnosis of lower extremity infections, 23
 Of erythrasma, 37
 And fungal infections, 160-161
 And onychomycosis, 172, 173
 Of tinea pedis, 160-161
- Fungal culture technique of dystrophic nail, 173
- Fungal infections. 155-190. *See also specific infection.*
 Cure vs. arrest of, 182
 As diabetic foot infections, 128
 In diagnosis of lower extremity infections, 26
 Erythrasma vs., 37
 Predisposing factors for, 158
 Preventive maintenance and, 182
 Septic arthritis due to, 80
 Travelers with, 9
- Fungal organisms
 Classification of pathogenic, 155-156
 Madura foot due to, 52
 Onychomycosis due to, 168-188
 Resistance of, 161
 Tinea pedis due to, 156-168
- Furuncles, 38, 329
- Fusobacterium*, 305, 307-308
 In bite wound infections, 95
 In trauma wound infections, 84t
- G**
- Gallium scans, 64
- Gangrene
 In arterial ulcerations, 127
 In hematogenous osteomyelitis, 74
 Infected vascular form of, 46-47
 In moderate infections, 123
 From *N. meningitidis*, 305
 Onychomycosis and, 169
 In secondary osteomyelitis, 76
 In synergistic necrotizing cellulitis, 44
- Garre’s sclerosing osteomyelitis, 63
- Gas gangrene, 45-46
 Due to *C. perfringens*, 302
 Infected vascular gangrene vs., 46
- Gastroenteritis, *Salmonella*-induced, 312
- Gastrointestinal flora
 Alcaligenes in, 314
 Bacteroides in, 306
 Enterococci in, 300
 V. vulnificus in, 318
- Gastrointestinal side effects
 Due to antibiotic usage, 216-218
 Due to macrolides, 287, 288, 289
 Due to tetracyclines, 290

- Gatifloxacin (Tequin), 280
- Gault, M.H., 17, 266
- Generic names of antibiotics, 347a-353a
- Genetic alterations of organisms, 203-204
- Genetic predisposition/abnormalities
 - To aminoglycoside toxicity, 264
 - To fungal infections, 158, 162
 - To hemolysis with sulfonamides, 207
- Gentamicin (Garamycin), 263
 - Daily doses of, 265-268
 - For dead space management, 70
 - Against *Serratia*, 264
 - For noninfected mal perforans, 120
 - Nephrotoxicity and, 269
 - Normal blood levels of, 267
- Geophilic organisms, 157
- Glossitis, 218
- Gloves, surgical, 138
- Glucose control, 107
- Glucose level, serum
 - In diagnosis of lower extremity infections, 18
 - In mildly infected ulcerations, 121
 - In moderately to severely infected ulcerations, 123
 - In septic arthritis, 79
- Glucose-6-phosphate dehydrogenase deficiency
 - Due to antibiotic usage, 207, 220
 - Sulfonamide side effects in, 285
- Glycocalyx
 - Bacteroides* forming, 306
 - Clindamycin dissolving, 149, 272
 - Implants causing, 135-136
 - Organisms forming, 141
- Glycopeptide antibiotic, 273
- Gonococcal (GC) arthritis, 80, 304
- Gonococcemia, 78
- Gonococci
 - Appearance of, 20t
 - Ceftriaxone against, 254
 - Penicillin G and, 231
 - Third-generation cephalosporins against, 245
 - Ticarcillin/ clavulanic acid against, 239
- Gonococci, non-penicillinase-producing, 228, 231
- Gonococci, penicillin-resistant, 304
- “Gorillamycin”, 259
- Gout
 - Cellulitis vs., 10
 - Osteomyelitis vs., 62
 - Septic arthritis vs., 78
- Gouty arthritis, acute, 31
- Gram stain. *See also* Staining and culturing techniques, special
 - Anaerobic bacteria in, 21
 - Of bone culture specimen, 61
 - Of clostridial myonecrosis, 45
 - Contamination of, 21
 - In diagnosis of lower extremity infections, 19
 - Of erythrasma, 37
 - Of impetigo, 39
 - Of infected vascular gangrene, 46
 - Of joint in septic arthritis, 78, 79
 - In moderate infections, 123
 - Of necrotizing fasciitis, 43, 44
 - After puncture wound trauma, 91
 - Of pyomyositis, 47
 - Of synergistic necrotizing cellulitis, 44
 - Wound closure and, 87
- Gram stain technique
 - Collecting specimen for, 194-195
 - In diagnosis of lower extremity infections, 19-21
- Gram –negative cocci, 304-305
- Gram-negative organisms
 - Appearance of, 20t
 - In bite wound infections, 95
 - In burn wound infections, 98
 - In clostridial myonecrosis, 45
 - In diabetic foot infections, 111
 - In hematogenous osteomyelitis, 73
 - In impetigo, 39
 - In infected vascular gangrene, 46
 - In moderate to severely infected ulcerations, 123
 - In open fracture infections, 101
 - In secondary osteomyelitis, 77
 - In septic arthritis, 79
 - In synergistic necrotizing cellulitis, 44-45
 - Tissue gas due to, 42
- Gram negative organisms (drug activity in)
 - Amikacin for resistant, 93, 264
 - Aminoglycosides against, 264, 269
 - Aminopenicillins vs. penicillins against, 232
 - Amoxicillin/ clavulanic acid against, 240
 - Ampicillin against community-acquired, 233

- Ampicillin/ sulbactam vs. other combinations against, 241
- Azithromycin against some, 288
- Aztreonam against aerobic, 262
- Aztreonam vs. aminoglycosides against, 263
- Aztreonam with clindamycin against, 263
- Cefazolin against, 148-149, 247
- Cefdinir against community-acquired, 256
- Cefepime vs. ceftazidime against, 258
- Cefoperazone vs. cefotaxime against, 255
- Cefotaxime against typical, 253
- Cefotetan vs. cefoxitin, 250
- Cefoxitin vs. cefazolin against, 249
- Ceftazidime similar to cefotaxime against, 255
- Cefuroxime against, 250
- Cefuroxime axetil against, 251
- Cephalexin against some, 248
- Cephalosporins against , 245, 246
- Ciprofloxacin against all common, 281
- Ciprofloxacin against severe infections with, 283
- Clarithromycin vs. azithromycin against, 288
- Drug resistance to, 204
- Ertapenem for mixed infections with, 261
- Erythromycin against a few, 287
- Imipenem/ cilastatin against most, 259
- Levofloxacin against, 283
- Meropenem vs. imipenem against, 260
- Metronidazole against anaerobic, 270
- Mezlocillin similar to ticarcillin against, 236
- Nafcillin ineffective against rods of, 234
- Penicillins' action in, 230
- Rifampin against some, 279
- Tetracyclines against some, 289
- Ticarcillin/ clavulanic acid against, 239
- Trimethoprim/sulfamethoxazole against, 285
- Vancomycin ineffective against, 273
- Gram-negative rods, aerobic. *See also* Enterobacteriaceae, 307-313
- Gram-negative rods, anaerobic, 305-307
- “Gram-negative tinea”, 157
- Gram-positive bacilli, 302-304
- Gram-positive cocci, 295-302
- Gram-positive cocci, anaerobic, 301-302
- Gram-positive organisms
 - Appearance of, 20t
 - In bite wound infections, 95
 - In clostridial myonecrosis, 45
 - In erythrasma, 37
 - In impetigo, 39
 - In infected vascular gangrene, 46
 - In mildly infected ulcerations, 121
 - In moderate to severely infected ulcerations, 123
 - In pyomyositis, 47
 - In secondary osteomyelitis, 77
 - In synergistic necrotizing cellulitis, 44
 - Tissue gas due to, 42
- Gram-positive organisms (drug activity in)
 - Agents against, 272-280
 - Ampicillin/sulbactam against, 240
 - Azithromycin against common, 288
 - Aztreonam/clindamycin against, 263
 - Cefdinir against, 257
 - Cefepime against, 258
 - Cefoperazone vs. cefotaxime against, 255
 - Cefotaxime against, 253
 - Cefotetan vs. cefoxitin against, 250
 - Cefoxitin vs. cefazolin against, 249
 - Ceftriaxone vs. cefotaxime against, 254
 - Cefuroxime axetil against, 251
 - Cephalexin against community acquired, 248
 - Cephalosporins against, 243-246
 - Ciprofloxacin not used for osteomyelitis with, 283
 - Clarithromycin vs. azithromycin against, 288, 289
 - Clindamycin against most, 271
 - Ertapenem for mixed infections, 261
 - Ertapenem vs. imipenem against, 261-262
 - Imipenem/ cilastatin against, 259
 - Levofloxacin against, 284
 - Linezolid against all, 276
 - Meropenem vs. imipenem against, 260-261
 - Metronidazole against anaerobic, 270
 - Moxifloxacin vs. ciprofloxacin against, 284
 - Penicillin G against, 232
 - Penicillins' action in, 228

Quinupristin/dalfopristin for serious infections with, 275
Ticarcillin/ clavulanic acid against, 239
Vancomycin against all, 273
Granulocytopenia, 183, 219, 224
Granulomas, 52
Grayson, M.L., 58
“Greasing the needle”, 40, 74
Green-nail syndrome, 317
Griseofulvin (Fulvicin, Gris-Peg, Grisactin)
History of, 155, 168, 175, 181
For onychomycosis, 183-184
And peripheral neuropathy, 214
For tinea pedis, 167-168
Growth factors for wound healing, 119
Gustilo, R.B., 101

H

Haemophilus

Cefaclor vs., 251
Rifampin against, 279
Ticarcillin/ clavulanic acid against, 239

Haemophilus influenzae, 316

Ampicillin and, 233
Cefuroxime against, 251
Cefaclor against, 251
Hematogenous osteomyelitis due to, 73
Second-generation cephalosporins against, 243
Septic arthritis due to, 79

Half-life, drug, 101, 147, 148, 149, 150, 204, 231, 246, 247, 249, 251, 253, 254, 255

Hamburger, contaminated, 309

Headaches due to ciprofloxacin usage, 281

Health and Human Services, U.S. Department of, 156

Hearing deficit

Due to aminoglycoside, 265
Due to antibiotic usage, 213

Heat

In cellulitis, 10
In mildly infected ulcerations, 121
In paronychia, 34
In secondary osteomyelitis, 75

Hematocrit, 45

Hematogenous osteomyelitis

Blood culture differentiation of, 60
Classification of, 55-56
Differential diagnosis of, 58

Hematogenous osteomyelitis, acute, 72-74
Bone scan differentiation of, 64

Types of patients with, 72

Hematogenous septic arthritis, 77

Hematoma, 134-135

Hemodialysis, 74, 275

Hemolytic anemia

Due to antibiotic usage, 224
Due to sulfonamide, 220, 285

Hendersonula. See *Scytalidium dimidiatum*, 157

Hepatic dysfunction

And antibiotic selection, 208
Erythromycin and, 213
Clindamycin dosage in, 271
Metronidazole and, 270
Nafcillin dosage and, 235

Hepatitis B, 84t

Hepatotoxicity, 216, 287

Hexachlorophene, 86

99m Tc-hexamethylpropylene amine oxime (HMPAO) scan

Of Charcot joint, 106
Of osteomyelitis, 65, 67

History, See Patient history.

Homan's sign, 34

Home intravenous antibiotics, 211-212

Honey for wound care, 86

Hookworm, 53

Hospital Infections Program of the National Center for Infectious Diseases, 134

Hospital personnel and surgical site infections, 141

Hospitalization

Acinetobacter infections and, 313
Bacterial culture procedure during, 195-196

CA-MRSA and, 290

CDAD and, 217

Citrobacter infections and, 308

Enterobacter infections and, 308

Home IV antibiotics for refusal of, 211

Infection rate related to length of, 137

For lower extremity infections, 26-27

For osteomyelitis, 68

For severe diabetic ulcerations, 126

Use of imipenem during, 259

“Hot tub dermatitis”, 37-38

Human bite wound infection

Amoxicillin/ clavulanic acid for, 240

E. corrodens in, 315

Organisms causing, 84t

Variables resulting in, 94

Human granulocytic Anaplasmosis (HGA), 51

HIV (Human immunodeficiency virus)
 Diagnosis of lower extremity infections with, 8
 Proximal white onychomycosis in, 171
 Site infections with, 7
Hydrogen peroxide irrigation, 42
Hydroxypyridone antifungal, 167
Hygiene, personnel, 141
Hyperbaric oxygen therapy
 For clostridial myonecrosis, 46
 For infections with *C. perfringens*, 303
 For osteomyelitis, 72
Hyperemic flush, 127
Hyperglycemia
 In diabetic Immunopathy, 107
 In diagnosis of lower extremity infections, 18
 In infected vascular gangrene, 46
 In neuropathy, 104
Hyperkeratosis
 In distal subungual onychomycosis (DSO), 171
 In noninfected mal perforans, 117
 Toenail removal and, 177
Hypernatremia, 18, 236
Hyperpigmentation, 28
Hypersensitivity
 To cephalosporins, 246
 Immediate vs. delayed, 233
 To penicillins, 230
 To sulfonamides, 285
Hypertension, infection with, 7
Hypokalemia
 Due to ticarcillin, 236
 From ticarcillin/ clavulanic acid, 239
Hypoprothrombinemia, 219
Hypotension, antibiotic usage and, 220-221

I

Imaging, diagnostic, 62-66
Imipenem
 Against *Acinetobacter*, 259, 313
 For infections with *C. perfringens*, 303
 For marine puncture wounds, 93
 For mycobacteria infections, 319
 With other antibiotics, 225
 And seizures, 214
Imipenem and cilastatin (Primaxin), 259-260
 For clostridial myonecrosis, 46
 For necrotizing fasciitis, 44
 For moderate to severely infected

 ulcerations, 125
Immune deficit
 In burn wound infections, 97
 In lower extremity trauma, 83
 In proximal white onychomycosis, 171, 172
 In surgical site infections, 139
Immune status
 Antibiotic selection and, 208
 Beta-hemolytic streptococci and, 299
 C. canimorsus and, 315
 Corynebacterium and, 303
 Mycobacterium and, 318-319
 S. maltophilia and *B. cepacia* and, 318
 Surgical prophylaxis and, 145
Immunization. *See* Tetanus prophylaxis
Immunoassay, 26
Immunofluorescence, 26
Immunologic techniques, 25-26
Immunopathy, 104, 107
Immunosuppression
Impetigo, 39-40, 329, 340,
Implants, surgical
 Antibiotic prophylaxis for, 145, 146
 CNS-infected, 298
 Corynebacterium infecting, 303
 Dental procedures after, 152-153
 Infection in, 135-136
 S. epidermidis causing infection after, 298
 Vancomycin for, 275
Indifference drug interaction, 209
Indium scans, 64-65
Infants, antibiotic selection for, 207
Infected vascular gangrene, 46-47
Infection, local site
 Antibiotics “masking”, 6
 Classification of diabetic, 113-115
 Clinical resolution, 28
 Definition of, 3-4
 Hospitalization of patient with, 26-27
 Hyperemic flush vs., 127
 Location of, for antibiotic selection, 208-209
 Number of bacteria for clinical, 85, 98
 Rules for diagnosis of, 115, 117
 Systemic infection vs., 3
IDSA (Infectious Diseases Society of America)
 42-44, 48, 50, 54, 110, 115, 122, 126, 129, 239-240, 242, 262, 272, 277, 279, 285, 335-336, 355

Inflammation of site infections, 4
Ingress-egress drainage flush
 After debridement, 71
 For septic arthritis, 80
Injection site infection, 40-41, 319
Inoculum effect, 206
Insecticides for prevention of Lyme disease, 50
Instruments, sterilization of surgical, 141
Insulin for wound care, 86
Insurance
 And home IV antibiotic therapy, 212
 And oral antifungal agents, 182
 And topical antifungal agents, 180
Intermittent bacteremia, 24
Intermittent fever, 12
Internet
 Alternative products from, 178
 Sites about infectious diseases on, 355a
Interstitial nephritis
 Due to antibiotic usage, 224
 Due to use of cephalosporins, 216
 Due to use of penicillins, 216
Intravenous drug abusers
 Diagnosis of lower extremity infections,
 6, 8, 9
 With hematogenous osteomyelitis, 72,
 74
 Home IV therapy contraindicated for,
 212
Intravenous route. *See* Parenteral therapy.
Intubation, endocarditis prophylaxis for
 anesthesia, 151
Invanz (ertapenem), 261-262
Iron supplements and ciprofloxacin usage, 282
Irrigation, wound
 Of bite wound, 96
 For infections following trauma, 85-86
 And surgical site infections, 137
 Tissue gas due to, 42
Ischemia
 And diabetic neuropathy, 104
 And diabetic ulceration, 111
 And secondary osteomyelitis, 77
Isoniazid and Griseofulvin, 214
Isopropyl alcohol for surgical scrub, 138
Isoxazolyl penicillins, 235
Itraconazole (Sporanox)
 History of, 155, 156, 176
 For onychomycosis, 185-186
Ivermectin, 53
Ixodid ticks, 48

Lyme disease, 48

J

Joint dysfunction and diabetic foot infections,
 109
Joint implants. *See* Implants, surgical.
Joint infections, 55-80
 Ceftazidime for, 255
 P. aeruginosa in, 317
Joint fluid aspiration
 For diagnosis of Lyme disease, 49
 For septic arthritis, 78, 80
The Journal of Infectious Diseases, electronic
 edition, 355a
"Jungle rot", 9

K

Kaleta, J.L., 59
Keflex. *See* Cephalexin.
Keftab. *See* Cephalexin.
Kefzol. *See* Cefazolin.
Ketoconazole (Nizoral)
 Dosage of, 165t
 History of, 181
 And onychomycosis, 184
 For tinea pedis, 167
Kidney disorders. *See* Nephrotoxicity; Renal
 impairment.
Kingella kingae, 305
Kirby-Bauer method, 197, 199, 334
Klebsiella, 310
 Appearance of, 20t
 Cefazolin against, 247
 Cephalosporins against, 245
 Drug resistance of, 204
 Ticarcillin/ clavulanic acid against, 239
K. pneumoniae, 247, 310

L

Laboratory tests
 For determining sensitivity of organism,
 197-198
 For diagnosis of bone and joint
 infections, 59-60
 For diagnosis of lower extremity
 infections, 15-18
 For identifying organisms, 195-196
Lacerations, antibiotic prophylaxis and, 137
Lamisil AT (terbinafine)
 Dosage of, 165t
 History of, 176, 181

- For onychomycosis, 187-188
 - For tinea pedis, 164, 166
 - Laser procedures, for paronychia, 36
 - Lateral subungual onychomycosis, 171
 - Left shift index
 - In cellulitis, 31
 - In diagnosis of lower extremity infections, 15-16
 - Legionella*, 26
 - Lemont, H., 159
 - Lethargy and fatigue, 49
 - Leukocytosis
 - In clostridial myonecrosis, 45
 - In diagnosis of lower extremity infection, 15
 - In erysipelas, 41
 - In infected vascular gangrene, 46
 - In necrotizing fasciitis, 43
 - In pyomyositis, 47
 - In sepsis, 14
 - In septic arthritis, 79
 - In severe infections, 126
 - In synergistic necrotizing cellulitis, 44
 - Leukopenia, 14, 50, 51
 - Levine technique, 23
 - Levofloxacin (Levaquin), 283-284
 - For bite wound infections, 96
 - For mildly infected ulcerations, 122
 - For moderate to severely infected ulcerations, 125
 - For puncture wound infections, 92
 - For surgical prophylaxis, 150
 - Leyden, 159
 - Lichen planus, 173
 - Limb salvage, 41
 - Lincomycin, 271
 - Linezolid (Zyvox), 276-277
 - Against CA-MRSA, 33
 - Against *Corynebacterium*, 303
 - Against HA-MRSA, 328
 - Against Madura foot, 52
 - For moderate to severely infected ulcerations, 125
 - Against MRSA, 335, 337
 - Against *S. aureus*, 297
 - For VRE, 301
 - Lipopeptide antibiotic, 277, 337
 - Lister, J., 131
 - Liver disorders. *See* Hepatic dysfunction; Hepatotoxicity.
 - Liver function tests (LFTs)
 - In diagnosis of lower extremity infections, 18
 - And penicillins, 230
 - Prior to antifungal therapy, 183
 - Loading dose, 266
 - Loprox (ciclopirox)
 - Dosage of, 165t
 - For onychomycosis, 176
 - For tinea pedis, 167
 - Loracarbef (Lorabid), 252
 - Lotrimin AF (clotrimazole), 165t, 166
 - Lotrisone (clotrimazole and betamethasone dipropionate), 165t, 166
 - Lyme borreliosis, 48, 49, 51, 254, 290
 - Lyme disease, 48-50
 - Doxycycline for, 50
 - Prophylaxis for, 50
 - Risk of, 50
 - Septic arthritis due to, 77
 - Stages of, 48-49
 - Transmission of, 48
 - Travelers with, 9
 - Lymphangiopathy, 31
 - Lymphadenitis, 11
 - Lymphadenopathy, 31
 - Lymphangitis, 6, 11
 - Lymphocyte ratio, 15
- M**
- Macrolides, 286-289
 - Vs. clindamycin, 271
 - For erythrasma, 37
 - Against *Kingella kingae*, 305
 - For marine puncture wounds, 94
 - Against *S. aureus*, 297
 - Mader, J., 56, 77
 - Madura foot, 51-52, 290
 - Maduromycosis, 51
 - Mafenide acetate cream, 99
 - Magnetic resonance imaging (MRI)
 - Of Charcot joint, 106
 - Of osteomyelitis, 62, 64, 65-67, 69
 - Of paronychia, 35
 - Of patient with septic arthritis, 78
 - Of post-puncture-wound osteomyelitis, 91
 - Of pyomyositis, 47
 - Maintenance doses, 266
 - Mal perforans ulcerations, noninfected, 115, 117-120
 - Arterial ulcerations vs., 126-127

- Contamination vs. infection in, 115, 117
- Pressure relief for, 118-119
- Wound care for, 119-120
- Males, Madura foot in, 52
- Malignancy
 - C. minutissimum* with, 304
 - Group G streptococci with, 300
 - Onychomycosis vs., 173
- Malpractice, medical, 132
- Mandol. *See* Cefamandole.
- Manual toenail debridement, 175-176
- Marine (water) injuries
 - A. hydrophilia* in, 314
 - M. marinum* in, 319
 - Pedal puncture wounds in, 93-94
 - V. vulnificus* in, 318
 - “Masked” infection, 6
- Matricectomy, 35, 36, 177
- Maxipime (cefepime), 244t, 257-258
- Mechanical debridement, 85-87
- Medical history in diagnosis of infection, 7
- Medicare, 27, 147, 169, 341
- Medline Internet site, 355a
- Mefoxin (cefoxitin), 244t, 248-249
- Meningococemia, 305
- Mentax (butenafine), 164, 165t
- Meropenem (Merrem), 260-261
 - Against *Acinetobacter*, 313
 - For *Kingella kingae* infection, 305
 - For moderate to severely infected ulcerations, 125
- Metallic taste, 270
- Methicillin, 229t
 - History of, 227
 - Vs. nafcillin, 234
 - Nephrotoxicity due to, 216
- Methicillin resistance. *See also specific antibiotic.*
 - Due to beta-lactamase production, 296
 - In injection site infections, 40
 - And surgical prophylaxis, 147
- Metronidazole (Flagyl), 270-271
 - Against anaerobic gram-positive cocci, 302
 - Antabuse reaction and, 221
 - Against *Bacteroides*, 306
 - For CDAD, 218
 - With ciprofloxacin, 283
 - Vs. clindamycin, 271
 - For clostridial myonecrosis
 - Against *C. tetani*, 302
 - Dosage of, 346a
 - E. corrodens* resistant to, 315
 - For injection site ulcerations, 40
 - Pregnancy and, 208
 - Vs. vancomycin, 274
- Mezlocillin (Mezlin)
 - With an aminoglycoside, 269
 - And platelet dysfunction, 219-220, 236
 - Vs. ticarcillin, 236
- Miconazole, 167
- Microbiology laboratory, antibiotic selection procedures by, 194-195
- Microsporum audouinii*, 157
- Migratory arthritis, 49
- Mildly infected ulcerations, 121-122
- Minimal inhibitory concentration (MIC)
 - Antibiotic-killing effects and, 205
 - Broth tube dilution technique for, 198
 - Drug in vitro activity and, 199
 - Inoculum effect and, 206
 - Interpretation and breakpoint of, 199
 - Postantibiotic effect (PAE) and, 206
 - Single daily dosing and, 268
- Minimum bactericidal concentration (MBC), 201
- Minocycline, 289-290
 - Dosage of, 246a
 - Against *M. marinum*, 319
 - For marine puncture wounds, 94
 - Vs. linezolid, 277
 - Against *S. maltophilia* and *B. cepacia*, 318
- Moccasin tinea pedis, 159, 186, 188
- Molds, 157, 160, 161, 162, 167, 170, 173, 180, 186
- Monobactams, 262, 272
- Morbidity
 - In arterial ulcerations, 127
 - In bite wound infections, 94
 - In diabetic foot infections, 110
 - After fixation of open fracture infections, 101
 - In fungal infections, 156
 - And MRSA, 330
- Morganella*
 - Beta-lactamase by, 238, 243
 - Ciprofloxacin against, 281
 - Ticarcillin against, 236
- Morganella Morganii*, 310
- Mortality
 - In burn wound infections, 100

- In necrotizing fasciitis, 43
 - In necrotizing infections, 41
 - Motor neuropathy, 105
 - Moxifloxacin (Avelox)
 - For bite wound infections, 96
 - For moderate to severely infected ulcerations, 125
 - MRSA, 323-342
 - Antibiotics for infections with, 332-340
 - In burn wound infections, 99
 - CA-MRSA vs. HA-MRSA, 327-328
 - Classification, 326-329
 - In community setting, 32-33, 216, 225, 285, 327-328, 342, 344
 - Cytolytic peptides and, 329
 - In diabetic foot infections, 125-126
 - In hematogenous osteomyelitis, 74
 - History of, 324-326
 - Infection control, 340-342
 - In hospital and community settings, 147
 - And impetigo, 39
 - Infection control, 340-342
 - In IV drug users, 74
 - Linezolid against, 337
 - Mupirocin against, 99
 - In open fracture infections, 101
 - Panton Valentine Leukocidin and, 328
 - Presentation, 329
 - Retapamulin against, 340
 - Significant resistance to ciprofloxacin of, 281
 - In severe infections, 126
 - In surgical setting, 138-139
 - As “therapeutic hole”, 210
 - Telavancin against, 339
 - Treatment, 330-340
 - MRSA, drug activity in
 - Cefazolin against, 247
 - Ceftaroline against, 258
 - Ceftobiprole against, 258
 - Cephalosporins against, 246
 - Ciprofloxacin ineffective against, 281
 - Ciprofloxacin and rifampin against, 281
 - Clindamycin against, 271, 272
 - Daptomycin against, 278
 - Doxycycline against, 289-290
 - Erythromycin ineffective against, 286
 - Minocycline against, 289, 290
 - Quinupristin/ dalfopristin against, 276
 - Rifampin against, 280
 - Tigecycline against, 279
 - Tetracyclines against, 289-290
 - Trimethoprim/ sulfamethoxazole against, 285
 - Vancomycin against, 273
 - Mucin clot formation, 79
 - Multiple organ failure, 43
 - Mupirocin (Bactroban)
 - For burn wound, 99
 - And decolonization, 138, 341
 - For impetigo, 39
 - For noninfected mal perforans, 120
 - Against staphylococcal folliculitis, 37
 - Musculoskeletal Infection Society of N.A., internet site of, 354a
 - Myalgias, 276
 - Mycetoma, 9, 51, 52
 - Mycobacteria
 - From bone culture, 61
 - Clarithromycin against, 94
 - In marine puncture wounds, 94
 - Nontuberculosis type of, 318-319
 - Rapid growing species of, 319
 - Rifampin against, 280
 - In septic arthritis, 319
 - Mycobacterium, atypical, 318
 - Mycobacterium leprae*, 9
 - Mycobacterium marinum*, 94
 - Mycobacterium tuberculosis*, 73
 - Mycologic testing, 160
 - Mycoplasma*, 26
 - Mycosel agar, 160
 - Myocutaneous flap, 71
- N**
- Nafcillin, 229t
 - For cellulitis, 32
 - For pyomyositis, 47
 - For scalded skin syndrome, 38
 - Naftifine (Naftin), 164, 165t
 - Nail debridement, 172, 180
 - Nail lacquer, 178, 179
 - Nails, *See* Toenail.
 - Nasal carriage of staphylococci, 139
 - Nasogastric route for CDAD, 218
 - National Healthcare Safety Network, 131-132
 - National Nosocomial Infections Surveillance System (NNIS), 132
 - Nausea and vomiting
 - Due to aminoglycoside, 265
 - Due to antibiotic usage, 218, 220
 - Due to ciprofloxacin, 281

- Due to erythromycin, 287
 - Due to imipenem, 260
 - Due to tigecycline, 279
 - Necrotizing fasciitis
 - Beta-hemolytic streptococci in, 43, 299
 - Due to *C. perfringens*, 302
 - Due to *V. vulnificus*, 318
 - Imipenem/cilastatin for, 260
 - In marine puncture wounds, 93
 - In moderate to severely infected ulcerations, 123
 - Necrotizing infections
 - Anaerobic gram-positive cocci in, 301
 - Following burn trauma, 98
 - Following surgical tissue injury, 136
 - Following trauma, 85
 - Imipenem/ cilastatin for, 260
 - Vibrio vulnificus* causing, 318
 - Neisseria*, 279
 - Neisseria gonorrhoeae*, 304
 - Neisseria meningitides*, 305
 - Neosporin, 120
 - Nephrotoxicity, 214-216
 - And aminoglycoside dosage, 268
 - Due to aminoglycoside, 264-265
 - Due to antibiotic usage, 215-216
 - And Vancomycin, 274
 - Neurologic symptoms in Lyme disease, 49
 - Neuromuscular blockade, 314, 265
 - Neuropathy
 - Autonomic, 105–107, 109
 - Diabetic, 105
 - Motor, 105
 - Sensory, 103, 105
 - Neurotoxicity
 - Due to antibiotic usage, 214
 - Due to ciprofloxacin, 282
 - Due to *C. tetani*, 302
 - Neutropenia
 - Due to antibiotic usage, 219
 - Due to cephalosporins, 246
 - Due to nafcillin, 234
 - Due to penicillins, 230
 - With terbinafine, 187
 - Due to vancomycin, 274
 - Neutrophils
 - And beta-lactam agents, 219
 - In bite wound infections, 96
 - In burn wound infections, 97
 - And cytolytic peptides, 329
 - In infection following trauma, 83
 - Nizoral (ketoconazole)
 - Dosage of, 165t
 - History of, 181
 - And onychomycosis, 184
 - For tinea pedis, 167
 - N-methylthiotetrazole (MTT) Sidechain
 - Antabuse reaction and, 221
 - Bleeding disorders due to, 220
 - In cefoperazone, 255, 256
 - In cefotetan, 249, 250
 - In cephalosporins, 246
 - Nocardia brasiliensis*, 52
 - Nontuberculous mycobacteria, 318-319
 - Nosocomial fever, 13-14
 - Nosocomial infections
 - Alcaligenes* in, 314
 - Cephalosporins for, 244
 - Ciprofloxacin for, 283
 - H. influenzae* in, 316
 - Morganella* in, 310
 - Mycobacterium in, 318
 - P. vulgaris* in, 311
 - Providencia* in, 311
 - Rates of, 132
 - Serratia* in, 312
 - Nuclear imaging, 62
 - Nurses and home IV antibiotic therapy, 212
 - Nutrition, patient, 139, 140
 - Nystagmus, aminoglycosides usage and, 265
- O**
- Obesity, infections in, 44, 140
 - Occupational Safety and Health Administration (OSHA) Internet site, 355a
 - Odor, foul
 - Associated with *Proteus*, 311
 - In dermatophytosis complex tinea pedis, 159
 - In diabetic foot infections, 124
 - In infected vascular gangrene, 46
 - In moderate to severely infected ulcerations, 124
 - And wound closure, 87
 - Ofloxacin (Floxin), 122
 - Omnicef (cefdinir), 244t, 256-257
 - Onychomycosis, 168-188
 - Clinical presentation and classification, 170–172
 - Definition of, 169
 - Diagnosis, 172–174
 - Differential diagnosis of, 172

- Facts and figures about, 168-169
 - History of therapy for, 155
 - Microbiology of, 170
 - Monitoring antifungal therapy for, 183
 - Oral agents for, 183-188
 - Oral antifungals and, 181-182
 - Topical antifungals, 178-181
 - Treatment, 175-188
 - Operating room environment and surgical site infections, 141
 - Oral cavity flora, 306
 - Oropharynx surgery, endocarditis prophylaxis and, 151
 - Osteomyelitis, 55-72
 - Acute hematogenous, 64, 72-74
 - Anatomic stages, 56
 - Ancillary management, 71-72
 - Antibiotic treatment for, 67-69
 - Bone culture for diagnosis of, 60-61
 - Ceftazidime alone for, 255
 - Charcot joint vs., 106
 - Ciprofloxacin for, 283
 - Classification of 55-57
 - Clindamycin for, 272
 - Cure vs. arrest of, 67
 - Dead space management, 70-71
 - Diagnosis, 57-59
 - Fixation devices for, 71-72
 - Groups C and G streptococci causing, 299-300
 - H. influenzae* in, 316
 - History taking for, 57-59
 - Home IV antibiotic therapy for, 212
 - Host types with, 56-57, 77
 - Hyperbaric oxygen therapy for, 72
 - Imaging for diagnosis of, 62-67
 - Kingella kingae* in, 305
 - Laboratory findings, 59-60
 - Open fractures, 84, 100-101
 - P.aeruginosa* in, 317
 - Paronychia and, 34
 - Penicillin G for, 232
 - Physiologic class, 56-57
 - P. multocida*, 316
 - Pseudomonal, 40, 144, 236-238, 255-257, 282, 284
 - Puncture wounds and, 5, 26, 31, 64, 75, 78, 80, 84, 87-89, 91-93, 144, 318
 - S.aureus* major cause of, 296
 - Salmonella* in, 312
 - Secondary to contiguous focus or direct extension, 74-76
 - Secondary to vascular insufficiency, 76-77
 - Septic arthritis with, 77
 - Surgical treatment for, 69
 - Treatment principles for, 67-69
 - Types of, 55-57, 72-77
 - Ototoxicity
 - And aminoglycosides dosage, 268
 - Due to aminoglycoside, 265
 - Due to antibiotic usage, 213-214
 - Vancomycin usage and, 274
 - Over-the-counter products for onychomycosis, 178
 - Oxacillin, 229t, 296, 325
 - Oxazolidinone antibiotic, 276, 337
 - Oxiconazole (Oxistat), 165t, 167
 - Oxygen therapy, hyperbaric. *See* Hyperbaric oxygen therapy.
 - Oysters, *Vibrio vulnificus* in raw, 318
- P**
- Pain. *See also* Calf tenderness; Skin tenderness.
 - In arterial ulcerations, 127
 - In clostridial myonecrosis, 45
 - In dermatophytosis complex tinea pedis, 159
 - In hematogenous osteomyelitis, 73
 - In hematoma vs. infection, 134
 - And infected vascular gangrene, 46
 - In necrotizing fasciitis, 43
 - In onychomycosis, 169
 - In osteomyelitis, 57
 - In post-op streptococcal infections, 299
 - In pyomyositis, 47
 - In secondary osteomyelitis, 76
 - In septic arthritis, 78
 - From stingray envenomation, 94
 - In synergistic necrotizing cellulitis, 44
 - Papineau grafting, 71
 - Parasitic infections, 51-53
 - Parenteral therapy and CDAD, 217
 - See also* Antibiotic therapy; *specific antibiotic.*
 - Paronychia 34-36, 170, 311
 - Pasteur, Louis, 131
 - Pasteurella*, 95
 - Pasteurella canis*, 84t
 - Pasteurella multocida*, 316
 - Septic arthritis due to, 80

- In trauma wound infections, 84t
- Patient education
 - Vs. drug promotion, 155
 - And home IV antibiotic therapy, 212
- Patient history
 - And antibiotic resistance, 196
 - Of bite wound trauma, 96
 - In diagnosis of bone and joint infections, 57-59
 - In diagnosis of lower extremity infections, 4-9
 - Of pedal puncture wound trauma, 88
- Patient nutrition and infection, 140
- Patient preparation for reducing infection, 137-138
- Peak serum levels, 267, 268, 336
- Peak specimen, 202
- Pedal puncture wound infections, 87-94
 - In bone, 93-94
 - In marine environment, 93-94
 - Primary care for, 88-89
 - In soft tissue, 92
 - Statistical data about, 88
 - Tetanus prophylaxis for, 90t
- Penems. *See* Carbapenem antibiotics
- Penicillin G, 229t, 230-232
 - For clostridial myonecrosis, 46
 - Forms of, 230-231
 - History of, 227
 - Interstitial nephritis due to, 216
 - Against *S. aureus*, 297
- Penicillin, penicillinase-resistant, 234-235
 - E. corrodens* resistant to, 315
 - P. multocida* resistant to, 316
- Penicillin resistance
 - And ampicillin, 233
 - Of anaerobic gram-negative rods, 307
 - Of *Bacteroides*, 306
 - In gonococcal infections, 304
 - Of group G and viridans streptococci, 300
 - And ticarcillin, 236
- Penicillin V, 229t, 232
- Penicillin-binding protein (PBP), 228
- Penicillins, 227-242
 - Adverse reactions to, 230
 - Aminoglycosides given with, 211, 268, 300
 - Aminopenicillins subgroup of, 232-234
 - Aztreonam for patient allergic to, 263
 - Beta-lactamase inhibitors with, 238-242
 - CDAD due to, 217
 - Cephalosporin reactions and, 224-225, 246
 - Classification of, 229t
 - For clostridial cellulitis, 232
 - For donor-leg cellulitis, 34
 - Dosages of, 346a
 - For endocarditis prophylaxis, 151
 - For erysipelas, 41
 - For impetigo, 39
 - And monobactams, 225
 - Nephrotoxicity due to, 216
 - Neutropenia due to, 219
 - Platelet dysfunction due to, 220
 - During pregnancy, 208
 - Seizures due to, 214
 - Semisynthetic subgroup of. *See* Penicillins, penicillinase-resistant.
 - For tetanus, 302
 - Ureido- and carboxy- subgroups of. *See* Penicillins; expanded-spectrum.
- Penicillins, drug activity of
 - Aeromonas* resistant to, 314
 - Against anaerobic gram-positive cocci, 302
 - Bacteroides* resistant to, 306
 - Against *C. canimorsus*, 315
 - Against *C. perfringens*, 303
 - Vs. *cefazolin*, 247
 - Vs. cephalalexin, 248
 - Vs. cephalosporin activity, 242, 247
 - Against *E. corrodens*, 315
 - Against enterococci, 301
 - Against *Fusobacterium*, 306-307
 - Against gonococci, 304
 - Against group G streptococci, 300
 - Against *Kingella kingae*, 305
 - Mechanism of action in, 228
 - Against *P. multocida*, 316
 - Vs. piperacillin, 237
 - S. maltophilia* and *B. cepacia* resistant to, 318
 - Against systemic *N. meningitidis*, 305
 - Vs. ticarcillin, 236
- Penicillins, aminopenicillins, 232-234
 - List of agents in, 229t
 - Spectrum of activity, 228-229
- Penicillins, expanded-spectrum, 236-238
 - Against *Citrobacter*, *Morganella*, *Serratia*, 308, 310, 313

- Against *E. coli* and *Klebsiella*, 309, 310
 - List of agents in, 229t
 - Spectrum of activity by, 230
- Penicillins, natural, 230-232
 - List of agents in, 229t
 - Nafcillin vs., 234
 - Spectrum of activity by, 228
- Penicillins, penicillinase-resistant, 234-235
 - For cellulitis, 32
 - Vs. ciprofloxacin, 283
 - For donor-leg cellulitis, 34
 - List of agents in, 229t
 - Spectrum of activity by, 229
 - And surgical prophylaxis, 147
- Penlac (ciclopirox nail lacquer), 179-180
- Peptococcus*, 301-302
 - Cefazolin against, 247
 - In moderate to severely infected ulcerations, 123
 - Synergistic necrotizing cellulitis due to, 45
- Peptostreptococcus*, 301-302
 - Cefazolin against, 247
 - In moderate to severely infected ulcerations, 123
- Periodic acid-Schiff (PAS) preparation, 161, 174
- Peripheral artery disease, 107, 129
- Peripheral neuropathy, 46, 110, 214, 277
- Peripheral vascular disease 7, 41, 46, 110
- Pets, infections and, 8
- Pexiganan (non-FDA approved), 122
- Pharmaceutical industry
 - Drug in vivo activity reported by, 203
 - Promotion of oral antifungals by, 181
 - Promotion vs. education by, 155
- Pharmacokinetics, of antibiotics, 204-205
- Phenol and alcohol procedure, 35-36
- Phenoxymethyl penicillin., 232
- Phlebectomy, cellulitis following, 33-34
- Phlebitis
 - Due to cephalosporins, 246
 - Due to IV quinupristin/dalfopristin, 276
- Photosensitivity
 - Due to antibiotic usage, 333
 - Due to ciprofloxacin, 282
 - Due to griseofulvin, 183
 - Due to tetracyclines, 290
- Physical examination
 - In diagnosis of bone and joint infections, 57-59
 - In diagnosis of lower extremity infections, 9-14
 - In pedal puncture wound trauma, 89
- Physicians' Desk Reference*
 - Drug renal clearance information in, 208
- Piperacillin (Pipracil), 237-238
- Piperacillin/ tazobactam (Zosyn), 241-242
 - For bite wound infections, 96
 - Against enterococci, 301
 - Vs. ertapenem, 262
 - For infected vascular gangrene, 47
 - For moderate to severely infected ulcerations, 125
 - For post-puncture-wound- osteomyelitis, 93
 - For puncture wound infections, 92
- Pityriasis rubra pilaris, 173
- Plantar space infections, 128
- Platelet dysfunction, 219-220, 236
- Pneumonia, 13, 286, 329
- Pneumocystis 286
- Podiatric patients, 33
- Podiatric physician
 - Manual toenail debridement by, 169
 - Onychomycosis patients of, 169
 - Oral antifungal most ordered by, 166
 - On oral antifungal therapy, 182
- Polymerase chain reaction (PCR), 26, 49, 79, 174, 195
- Polymorphonuclear leukocytes (PMNs), 15, 16, 20, 21
- Popliteal fossa, 11
- Porphyromonas, 84t, 95, 305, 306-307
- Porphyromonas asaccharloytica*, 306
- Postantibiotic effect (PAE), 206, 268
- Postoperative infections. *See also* Surgical site infections.
 - Beta-hemolytic streptococci in, 299
 - Cellulitis in, 10
 - Clostridial myonecrosis in, 45
 - Contiguous focus osteomyelitis as, 74-76
 - Costs of, 132
 - Etiologies of, 5
 - Necrotizing fasciitis as, 43
 - Septic arthritis as, 78
 - Tissue gas in, 42
- Potassium hydroxide (KOH) preparation, diagnostic
 - In diagnosis of lower extremity infections, 23

- For onychomycosis, 172, 173
- For tinea pedis, 160
- Potassium level, 18
- Povidone iodine (Betadine)
 - And decolonization, 341
 - For infections following trauma, 86
 - For noninfected mal perforans, 119, 120
 - For puncture wound infections, 89
- Pregnancy
 - Antibiotic selection during, 208
 - And tetracycline, 208, 216, 290
- Preoperative preparation for reducing infection, 137-139
- Pressure relief for noninfected mal perforans, 118
- Prevotella melaninogenica*, 306
- Primaxin. *See* imipenem and cilastatin.
- Probenecid
 - Amoxicillin with, 234
 - Ampicillin with, 233
 - Cefazolin and, 247
 - Cephalexin and, 248
 - Cloxacillin and dicloxacillin with, 235
 - Nafcillin with, 234
 - Penicillin G with, 231
 - Ticarcillin with, 236
- Procaine penicillin, 230, 231
- Proctoscopy, for diagnosis of CDAD, 217
- Prostaglandin production, drugs inhibiting, 11-12
- Prosthetic joint implants. *See* Implants, surgical.
- Protein binding of drug, 205
 - Cefoperazone and, 255
 - Ceftriaxone and, 254
- Proteus*
 - Azithromycin against, 288
 - In moderate to severely infected ulcerations, 123
 - Second-generation cephalosporins against, 245
 - Ticarcillin against, 236
 - In trauma wound infections, 84t
- Protein mirabilis*
 - And ampicillin, 233
 - Cefazolin against, 247
 - First-generation cephalosporins against, 245
 - Foot flora with, 311
 - Noninfected mal perforans and, 118
 - Paronychia due to, 35
 - Tinea pedis and, 157
- Proteus Morganii*. *See* *Morganella Morganii*.
- Proteus vulgaris*, 310-312
- Prothrombin time, 220
- Providencia*, 311-312
- Proximal white onychomycosis, 171
- Pruritus
 - Due to antibiotic usage, 221, 223
 - In cutaneous larva migrans (CLM), 53
 - In erythrasma, 37
 - Due to vancomycin, 274
 - In vesicular tinea pedis, 159
- Pseudomembranous colitis, 216, 218, 233, 271
- Pseudomonas aeruginosa*, 317
 - In burn wound infections, 99
 - Ecthyma due to, 40
 - Folliculitis due to, 37
 - Hematogenous osteomyelitis due to, 74
 - Infections caused by, 5
 - In IV drug users, 8
 - In marine puncture wounds, 93
 - Noninfected mal perforans and, 118
 - Onychomycosis vs., 170
 - Osteomyelitis due to, 74, 80
 - Paronychia with, 35
 - Septic arthritis due to, 80
 - Tinea pedis and, 157
 - In trauma wound infections, 84t, 90
- Pseudomonas aeruginosa*, drug activity in,
 - Aminoglycosides against, 263
 - Aztreonam against, 262
 - Beta-lactamase inhibitor combinations against, 238
 - Cefdinir ineffective against, 256
 - Cefepime against, 258
 - Cefixime and ceftibuten ineffective against, 257
 - Cefoperazone against, 255
 - Cefotaxime ineffective against, 253
 - Ceftazidime most active for, 255
 - Cephalosporins against, 243
 - Ciprofloxacin against, 281
 - Doripenem against, 262
 - Drug combinations against, 263
 - Ertapenem ineffective against, 261
 - Imipenem/ cilastatin and, 259
 - Levofloxacin less active against, 283
 - Levofloxacin vs. ciprofloxacin against, 283
 - List of antibiotics against, 354a
 - Meropenem against, 260
 - Moxifloxacin against, 284

Piperacillin against, 237
Ticarcillin against, 236
Tobramycin against, 264
Psoriasis vs. other infections, 171, 173
Pulmonary emboli, nosocomial fever with, 13
Pulse dosing
 Drug interactions with, 182
 Pros and cons of antifungal, 186
Pulse volume recordings, 127
Puncture wound infection *See also* Pedal
 puncture wound infections.
 Antibiotic prophylaxis and, 144
 Bone scan differentiation of, 91
 Contiguous focus osteomyelitis
 secondary to, 75
 Organisms causing, 84t
 Septic arthritis from, 78
 V. vulnificus causing, 318
Pus, skeletal muscle, 47
Pyomyositis, 47–48
Pyridoxine, 214
Pyrogens 11–14, *See also* Fever.

Q
QT interval changes, 280
Quality of life, 169
Quantitative bacteriology, 22, 87, 98
Quinine, 51
Quinolone resistance in non-US gonococcal
 infections, 304
Quinolones
 For bite wound infections, 96
 Clindamycin and, 272
 Vs. cefoperazone, 256
 Vs. cefotaxime, 253
 Dosages of, 346a
 For infected vascular gangrene, 47
 For marine puncture wounds, 93
 For moderate to severely infected
 ulcerations, 125
 For open fracture infections, 101
Quinolones, drug activity of
 Against *Aeromonas*, 314
 Against *B. henselae*, 315
 Against *C. canimorsus*, 315
 Against *Citrobacter*, *Morganella*,
 Serratia, 308, 310, 313
 Against *E. coli* and *Klebsiella*, 309, 310
 Against *E. corrodens*, 316
 Against *H. influenzae*, 316
 Against *Kingella kingae*

 Against *P. mirabilis*, 311
 Against *P. multocida*, 316
 Against *P. vulgaris* and *Providencia*,
 311
 Against *Salmonella*, 312
Quinupristin/ dalfopristin (Synercid), 275-276

R
Radiography
 Of bite wound, 96
 Of Charcot joint, 106
 Of clostridial myonecrosis, 45
 Of contiguous focus osteomyelitis, 75
 Of infected vascular gangrene, 46
 Of osteomyelitis, 62, 66
 Of paronychia, 33
 After pedal puncture wound trauma, 89
 Of puncture wound infections, 91
 Of septic arthritis, 78
Rajendran, P.M., 331
Rash
 Due to ampicillin, 233
 Due to antibiotic usage, 221, 223
 Due to cephalosporins, 246
 Due to rifampin, 280
 Due to sulfonamide, 285
 Due to tetracyclines, 290
Red man (Red neck) syndrome, 221, 274
Renal failure
 Amoxicillin dosage in, 234
 Amoxicillin/ clavulanic acid dosage in,
 240
 Ampicillin/ sulbactam dosage in, 241
 Cefazolin dosage in, 247
 Cefotaxime dosage in, 253
 Cephalexin dosage in, 248
 Clindamycin dosage in, 271
 Due to quinolones, 280
 Nafcillin dosage and, 235
 Single daily dosage and, 268
 Ticarcillin/ clavulanic acid dosage in,
 239
Renal function
 Antibiotic dosages and, 17, 18
 Metronidazole usage and, 270
 Normal, defined, 267
 Vancomycin usage and, 274, 336
Renal impairment. *See also* Creatinine levels,
 serum.
 Aminoglycosides toxicities and, 269
 Antibiotic selection in, 207-208

- Aztreonam dosage in, 263
 - Cefoperazone dosage in, 256
 - Cefotetan dosage in, 250
 - Cefoxitin dosage in, 249
 - Ceftazidime dosage in, 255
 - Ceftizoxime dosage in, 254
 - Ceftriaxone dosage in, 254
 - Cefuroxime dosage in, 250
 - Ciprofloxacin dosage in, 282
 - Cloxacillin and dicloxacillin dosage in, 235
 - Diabetic foot infections and, 109
 - Erythromycin dosage in, 287
 - Imipenem/ cilastatin dosage in, 260
 - Nephrotoxicity and, 215
 - Ototoxicity and, 231
 - Penicillin G dosage in, 231
 - Penicillin V dosage in, 232
 - Respiratory tract infections
 - Cefdinir for, 257
 - Cefixime and cefibuten for, 257
 - Clarithromycin for, 288
 - Klebsiella* in, 310
 - Viridans streptococci causing, 300
 - Retapamulin, 39, 340
 - Rheumatoid arthritis
 - Septic arthritis vs., 78
 - Septic arthritis with, 77
 - Surgical prophylaxis for, 146
 - Rifampin, 279-280
 - With ethambutol, 94, 319
 - With minocycline, 290, 297
 - With trimethoprim/ sulfamethoxazole, 52
 - With vancomycin, 219
- S**
- Sabouraud's agar, 160
 - Safety
 - Of aminoglycosides, 263, 264-265, 268
 - In antibiotic selection, 194
 - Of azithromycin vs. erythromycin, 287
 - Of aztreonam, 263
 - Of cephalosporins, 246
 - Of cloxacillin and dicloxacillin, 235
 - Of oral antifungals, 181
 - Of penicillins, 230
 - Of quinupristin/ dalfopristin, 275
 - Of "T&T" combination, 237
 - Of tetracyclines vs. other antibiotics, 289
 - Of vancomycin, 273
 - Saliva, injection site infections and, 40
 - Salmonella*, 312
 - Ampicillin and, 233
 - Cephalosporins against, 245
 - Hematogenous osteomyelitis due to, 312
 - Ticarcillin/ clavulanic acid against, 239
 - Salt water organisms, 319
 - Saphenous vein graft, cellulitis following harvesting of, 33
 - Saprophytic molds, 157, 170, 173
 - Sardinia, 242
 - Scalded skin syndrome, staphylococcal, 38
 - Scarring, osteomyelitis and, 59
 - Scans, 14, 63-65, 67, 75, 91, 106
 - Schlichter test, 201
 - Scintigraphy
 - Of osteomyelitis, 63
 - Paronychia and, 35
 - Scopulariopsis brevicaulis*, 170
 - Scytalidium dimidiatum*, 157, 170
 - Scytalidium hyalinum*, 157
 - Seizures
 - Due to antibiotic usage, 214
 - Due to doripenem, 262
 - And fevers, 12
 - Due to imipenem, 260
 - Due to meropenem, 261
 - Due to metronidazole, 270
 - Myoclonic, from penicillins, 230
 - Sensory neuropathy, 105
 - Sepsis, 14
 - Aminoglycosides, 269
 - In burn wound infections, 97, 98, 100
 - CNS and, 298
 - Criteria for diagnosis, 14
 - CRP indicator, 59
 - Differential diagnosis of, 9
 - Hospitalization for, 27
 - In severely infected ulcerations, 126
 - In necrotizing fasciitis, 43
 - P. aeruginosa* causing, 317
 - Vibrio vulnificus* causing, 318
 - Septic arthritis, 77-80
 - Bacterial etiology, 79-80
 - Bite wound infections causing, 94
 - Ceftriaxone for, 254
 - Differential diagnosis of, 78
 - Gonococcal infection and, 304
 - Gout vs., 78
 - Groups C and G streptococci, 298

- H. influenzae* causing, 316
- Kingella kingae* causing, 305
- Laboratory findings of, 79
- Osteomyelitis secondary to, 74
- Penicillin G and, 232
- Rapid-growth mycobacteria in, 319
- Treatment for, 80
- Types of, 77-78
- Septicemia. *See also* Bacteremia; Toxemia.
 - In clostridial myonecrosis, 46
 - In marine puncture wounds, 93
 - In pyomyositis, 47
 - In scalded skin syndrome, 33
- Septra, 285
- Serrati, 312
- Serratia*, 312-313
 - Beta-lactamase by, 238, 243
 - Ciprofloxacin against, 281
 - Gentamicin against, 264
 - Trimethoprim/ sulfamethoxazole and, 285
- Serum bactericidal titer (SBT), 201, 202
- Serum sickness, 224
- Shaving and infections, 137
- Shigella*, 229, 233, 245
- Shoes
 - And noninfected mal perforans, 119
 - And onychomycosis, 169
 - And tinea pedis, 158
- “Shotgun therapy”, 210
- Sickle cell disease, osteomyelitis in, 74
- Sigmoidoscopy for diagnosis of CDAD, 217
- Signs and symptoms in diagnosis of lower extremity infections, 5-6, 9-14
- Silvadene (silver sulfadiazine), 120
- Silver nitrate solution, 99
- Silver sulfadiazine (Silvadene)
 - For burn wound, 99
 - For noninfected mal perforans, 120
 - And wound care, 86
- Sinus tract, in osteomyelitis, 21, 57, 58
- Skeletal muscle, pyomyositis, 47
- Skin and soft tissue infections. *See also* Fungal infections.
 - Acinetobacter* in, 313
 - Amoxicillin/ clavulanic acid for, 92, 240
 - Ampicillin/sulbactam, 92
 - Azithromycin for, 288
 - Beta-hemolytic streptococci in, 299
 - Cefazolin, 92
 - Cefdinir for, 257
 - Cefpodoxime proxetil for, 257
 - Ceftazidime for, 255
 - Cephalexin, 92
 - Clindamycin, 92
 - Groups C and G streptococci in, 299
 - Levofloxacin for, 92, 284
 - Moxifloxacin for, 284
 - P. aeruginosa* in, 317
 - Piperacillin/tazobactam, 92
 - Vibrio vulnificus* in, 318
- Skin changes with infections/trauma, 97, 109
- Skin flora, 22, 25, 303
- Skin graft, 714, 99
- “Skin popped”, 40
- Skin tenderness, 38
- Smoking in diagnosis of lower extremity infections, 8
- “Sneaker osteomyelitis”, 92
- Soaks, foot. *See also* Compresses, warm.
 - And paronychia, 35
 - For puncture wound trauma, 89
 - For stingray envenomation, 94
- Social history in diagnosis of lower extremity infections, 8
- Society of Critical Care Medicine, 14
- Sodium hypochlorite (Dakin’s solution), 86, 120
- Sodium level, serum
 - In diagnosis of lower extremity infections, 18
 - And penicillin usage, 231
 - And ticarcillin/ clavulanic acid usage, 239
- Southern U.S.
 - Cutaneous larva migrans (CLM) in, 9
 - Madura foot in, 51
- Spectazole (econazole), 165t, 166-167
- Spleen, *C. canimorsus* in patients without, 315
- Spondyloarthropathies seronegative, 78
- Sporanox (itraconazole)
 - History of, 155, 181
 - For onychomycosis, 185-186
- Staining and culturing techniques, special
 - For Lyme Disease, 49
 - For Madura foot, 52
 - For onychomycosis, 161
- Staphylococcal scalded skin syndrome, 38
- Staphylococci
 - In bite wound infections, 95
 - In burn wound infections, 98
 - Carried by surgeon, 139
 - Furuncle and carbuncle due to, 38

- Indications for use of clindamycin
 - against, 271
- Infected vascular gangrene due to, 46
- In osteomyelitis, 59
- Paronychia due to, 35
- Staphylococci (drug activity in)
 - Aminoglycosides in drug combinations
 - against, 264
 - Amoxicillin/ clavulanic acid against, 240
 - Ampicillin/ sulbactam against, 241
 - Azithromycin against, 288
 - Cefazolin against, 247
 - Cefdinir against, 256
 - Cefepime against, 258
 - Cefpodoxime proxetil vs. cefdinir
 - against, 257
 - Cefprozil, 252
 - Ceftriaxone against, 255
 - Cefuroxime against, 250
 - Cephalexin vs. penicillins against, 248
 - Cephalosporins against, 243
 - Cloxacillin and dicloxacillin against, 235
 - Erythromycin against, 287
 - Levofloxacin vs. ciprofloxacin against, 283
 - Nafcillin against, 234
 - Piperacillin ineffective against, 237
 - Quinupristin/ dalfopristin against, 276
 - Resistance to ciprofloxacin of, 281
 - Rifampin against, 279
 - Tetracyclines against, 289
 - Ticarcillin and, 236
 - Ticarcillin/ clavulanic acid against, 238
 - Trimethoprim/ sulfamethoxazole
 - against, 285
- Staphylococci, coagulase-negative (CNS), 298, 326
- Staphylococci, non-penicillinase-producing. *See Staphylococcus aureus*, penicillin-sensitive.
- Staphylococci, penicillinase-producing. *See Staphylococcus aureus*, methicillin-sensitive.
- Staphylococcus*
 - Appearance of, 20t
 - Glycocalyx formation by, 141
 - Susceptibility of, 147
- Staphylococcus aureus*, 295-297
 - Antibiotics for infections with, 297
 - Cefazolin against non-resistant, 247
 - Cefepime against, 258
 - Ceftriaxone against, 255
 - Cellulitis due to, 32
 - Cephalosporins against, 242, 246
 - Clindamycin against, 271
 - Endocarditis prophylaxis against, 151
 - Folliculitis due to, 37
 - Gentamicin against, 269
 - Hematogenous osteomyelitis due to, 73
 - Impetigo due to, 39
 - Injection site infections due to, 40
 - Mildly infected ulcerations due to, 121
 - Moderate to severely infected
 - ulcerations due to, 123
 - Noninfected mal perforans and, 118
 - Notoriety and virulence of, 140
 - Open fracture infections due to, 100
 - Post-operative infections due to, 3
 - Puncture wound infections due to, 91
 - Pyomyositis due to, 47
 - Quinupristin/Dalfopristin against, 276
 - Resistance patterns of, 296-297
 - Scalded skin syndrome due to, 38
 - Septic arthritis due to, 79
 - Surgical prophylaxis against, 147
 - In trauma wound infections, 84t
 - Vancomycin against, 273
- Staphylococcus aureus*, methicillin-resistant (MRSA). *See* MRSA.
- Staphylococcus aureus*, methicillin-sensitive, 296
 - Antibiotics for infection with, 297
 - First-generation cephalosporins against, 245
 - Nafcillin against, 234, 296
 - Oxacillin against, 296
- Staphylococcus aureus*, penicillin-sensitive, 296
 - Antibiotics against, 297
 - First-generation cephalosporins against, 245
 - And penicillin G, 231
- Staphylococcus aureus*, vancomycin-intermediate (VISA).
 - in hospital and community settings, 147
- Staphylococcus epidermidis*
 - Contamination by, 25
 - Hematogenous osteomyelitis due to, 74
 - Infections caused by, 5, 6
 - In joint implant infections, 147
 - Latent infections due to, 140

- Noninfected mal perforans and, 118
- In prosthetic joint implants, 134
- In trauma wound infections, 84t
- Wound closure and, 87
- Staphylococcus epidermidis* methicillin-Resistant (MRSE).
 - In implant infections, 147
 - In surgical site infections, 5, 140
 - Vancomycin against, 273, 275
- Staphylococcus epidermidis*, vancomycin-resistant (VRE), 276, 298
- Stenotrophomonas maltophilia*, 317-318
 - Resistant to aztreonam, 262
 - Resistant to ciprofloxacin, 281
 - Trimethoprim/ sulfamethoxazole against, 285, 286
- Sterilization, surgical instrument, 141
- Steroids
 - Septic arthritis and, 77, 78
- Stevens-Johnson syndrome 221, 274, 285
- Stingray envenomation, 94
- Stomatitis due to antibiotic usage, 218
- Streptococci
 - In bite wound infections, 95
 - In burn wound infections, 98
 - Ecthyma due to, 40
 - Endocarditis prophylaxis for, 151
 - Paronychia due to, 35
 - In puncture wound infections, 91
- Streptococci, alpha-hemolytic, 84t
- Streptococci, drug activity in
 - Aminoglycosides/ beta lactam against, 264, 269
 - Amoxicillin/ clavulanic acid against, 240
 - Ampicillin against, 233, 237
 - Azithromycin against, 288
 - Cefazolin vs. penicillin against, 247
 - Cefdinir vs. cephalexin against, 256
 - Cefepime against, 258
 - Cefpodoxime proxetil vs. cefdinir against, 257
 - Cephalosporins against, 244
 - Ciprofloxacin unreliable against, 281
 - Clindamycin against, 271
 - Erythromycin against, 287
 - Levofloxacin vs. ciprofloxacin against, 283
 - Nafcillin vs. other penicillins against, 234
 - Penicillin G against, 231
 - Piperacillin and other penicillins against, 237
 - Rifampin against, 279
 - Tetracyclines against, 289
 - Ticarcillin vs. penicillin against, 236
 - Ticarcillin/ clavulanic acid against, 238
 - Trimethoprim/ sulfamethoxazole against some, 285
 - Vancomycin against, 273
- Streptococci, group A beta-hemolytic. *See also Streptococci pyogenes.*
 - Cellulitis caused by, 32
 - Donor-leg cellulitis due to, 34
 - Erysipelas due to, 41
 - Impetigo due to, 39
 - Injection site infections due to, 40
 - Limb necrosis due to, 134
 - Necrotizing fasciitis due to, 43
 - In trauma wound infections, 84t
- Streptococci, group B beta-hemolytic. *See also Streptococcus agalactiae.*
 - Common infections with, 5
 - Infected vascular gangrene due to, 46
 - In moderate to severely infected ulcerations, 123
 - Septic arthritis due to, 79
 - In trauma wound infections, 84t
- Streptococci, group D. *See Enterococci.*
- Streptococci, groups C and G beta hemolytic, 299-300
- Streptococci, viridans, 299-300
- Streptococcus*
 - Appearance of, 20t
 - In trauma wound infections, 84t
- Streptococcus agalactiae.* *See also Streptococci, group B beta-hemolytic, 298-299*
 - Mildly infected ulcerations due to, 121
- Streptococcus pyogenes.* *See also Streptococci, group A beta-hemolytic, 298-299*
- Subacute bacterial endocarditis (SBE) 9, 12
- Sugar for wound care, 86
- “Suicide agent”, 238
- Sulconazole (Exelderm), 165t, 167
- Sulfonamides, 285-286
 - Agranulocytosis due to, 219
 - Drug-drug interactions with, 207
 - Hemolytic anemia with, 207, 220
 - “Superbug”, 301
- Superficial infections, 31-41
- Superinfection, 120, 153, 218
- Suprax (cefixime), 257

- Surgeon preparation for reducing infection, 138-139
 - Surgery, endocarditis prophylaxis and elective, 150
 - Surgery length
 - Antibiotic prophylaxis and, 145
 - Infection rate related to, 137
 - Surgical apparel and surgical site infections, 141
 - Surgical debridement
 - Of bite wound, 96
 - Of burn wound, 99
 - For clostridial myonecrosis, 46
 - For contiguous focus osteomyelitis, 76
 - To diagnose necrotizing fasciitis, 42
 - Followed by dead-space management, 70-71
 - Followed by home IV antibiotic therapy, 212
 - During hospitalization, 27
 - For infections following trauma, 85
 - For infections with *C. perfringens*, 303
 - For marine puncture wounds, 93
 - For mildly infected ulcerations, 121
 - For mycobacteria-infected sites, 319
 - For necrotizing fasciitis, 43
 - For noninfected mal perforans, 119
 - For post-puncture-wound osteomyelitis, 68
 - For secondary osteomyelitis, 77
 - For synergistic necrotizing cellulitis, 45
 - Surgical drains, infection in, 135
 - Surgical incision and drainage
 - Of bite wound, 96
 - Endocarditis prophylaxis for, 150
 - Of furuncles and carbuncles, 38
 - Of infected puncture wounds, 92
 - Of *M. marinum*-infected lesion, 319
 - Of marine puncture wounds, 93, 94
 - Of moderate to severely infected ulcerations, 124
 - Of mycobacteria-infected sites, 319
 - Of pyomyositis pus, 47
 - Of septic arthritic joints, 80
 - Of *V. vulnificus*-infected wounds, 318
 - Surgical infections, 131-154
 - Antibiotic prophylaxis, 142-153
 - Dental and prosthetic joint patients, 152-153
 - Endocarditis prophylaxis, 150-153
 - Environmental factors, 141
 - Pathogen factors, 140-141
 - Patient factors, 139-140
 - Surgical factors, 133-139
 - Surgical prophylaxis, 145-146
 - Adverse effects and failures of, 153
 - Antibiotics agents for, 148-150
 - Antibiotic selection and administration for, 147-148
 - Cefazolin for, 247
 - Cefuroxime for, 251
 - Cephalexin for outpatient, 248
 - For risk of endocarditis, 150-151
 - Vancomycin for, 275
 - Surgical scrubs for reducing infection, 138-139
 - Surgical site infections (SSIs). 131-141 *See also* postoperative infections.
 - History and incidence of, 131-132
 - Operating room factors in, 141
 - Pathogen factors of, 140-141
 - Patient factors of, 139-140
 - Rapid-growing mycobacteria in, 319
 - Risk factors of, 132-133, 133f
 - Surgical factors of, 133-139
 - Surgical technique, breaches of, 134-139
 - Survival rate for leg amputees, 104
 - Sutures and sutures technique, infections caused by, 135
 - “Swarming” organism, 311
 - Swimming pools
 - Fungal infections and, 162
 - Puncture wounds and, 94
 - Synercid (Quinupristin/ dalfopristin), 275-276
 - Synergistic necrotizing cellulitis, 44-45
 - Synergy drug interaction, 209
 - Synovial fluid analysis, 79
 - Systemic lupus erythematosus, 221
- T**
- Tachycardia, 14, 45, 116t, 126, 220
 - Taste disturbances
 - Due to clarithromycin, 289
 - Due to metronidazole, 270
 - With terbinafine (Lamisil) usage, 187
 - Taylor, G.J., 142
 - Tea tree oil (*Melaleuca alternifolia*), 164, 178
 - Technetium 99 MDP bone scans
 - For diagnosis of osteomyelitis, 63-64, 65
 - In post-puncture-wound osteomyelitis, 91
 - Teeth, staining of, 290
 - Teichoic acid antibodies, 17, 59-60

- Telavancin, 339-340
- Tendonopathies, 282
- Tequin *See* Gatifloxacin.
- Teratogenicity, 208
- Terbinafine (Lamisil AT)
- Dosage of, 165t
 - History of, 155, 181
 - For onychomycosis, 187-188
 - For tinea pedis, 164, 166
- Tetanus prophylaxis
- Of bite wound trauma, 96
 - Indications for, 90t
 - After puncture wound trauma, 89
- Tetracycline, 289-290
- Children and, 207
 - Dermatologic reactions due to, 221
 - Dosage of, 346a
 - GI side effects due to, 218
 - Hepatotoxicity due to, 216
 - Against *Kingella kingae*, 305
 - For marine puncture wounds, 93, 94
 - Pregnancy and, 208
- Tetracyclines, 289-290
- Vs. macrolides, 289
 - Against *S. aureus*, 297
- Theophylline, 282, 284
- “Therapeutic holes”, 210
- Thermoregulation, 11
- Thiabendazole, 53
- Thienamycin, 259
- Thrombocytopenia
- In anaplasmosis, 51
 - By co-infecting zoonoses, 50
 - Due to linezolid, 219, 276
 - Due to penicillins, 230
 - Due to vancomycin, 274
- Thrombophlebitis. *See also* Deep vein thrombophlebitis (DVT).
- Vs. donor-leg cellulitis, 34
 - Due to erythromycin, 287
 - Due to tetracyclines, 290
 - Nosocomial fever with, 13
- Ticarcillin, 236-237
- Platelet dysfunction due to, 220
 - Pregnancy and, 208
- Ticarcillin/ clavulanic acid (Timentin), 238-239
- For bite wound infections, 96
 - For moderate to severely infected ulcerations, 125
 - Vs. piperacillin/ tazobactam, 239, 241
 - Against *S. maltophilia* and *B. cepacia*, 318
- Vs. ticarcillin alone, 239
- Tick-borne zoonoses, 50-51
- Timentin. *See* Ticarcillin/ clavulanic acid.
- “Tinea incognito”, 159
- Tinea pedis 156-168
- Cellulitis due to, 34
 - Clinical presentation, 158-159
 - Definition of, 156
 - Diagnosis of, 159-161
 - Erythrasma vs., 36
 - Microbiology of, 157-158
 - Oral agents for, 167-168
 - Topical agents for, 163-167, 165t
 - Treatment, 161-168
 - Types of, 158-159
 - Variants of, 156-157
- Tinea unguium, 169
- Tinnitus, 213, 265
- Tioconazole (non-FDA approved), 178
- Tissue gas
- In clostridial myonecrosis, 45
 - CT scan to locate, 66
 - In diabetic foot infections, 42
 - In infected vascular gangrene, 46
 - In moderate to severely infected ulcerations, 123
 - In necrotizing fasciitis, 43
 - In synergistic necrotizing cellulitis, 44
- Tissue infections. *See* Skin and soft tissue infections.
- Tissue penetration of drug, 204-205
- Tissue transplant, 71
- Tobramycin (Nebcin), 263
- Against *P. aeruginosa*, 264
 - For dead-space management, 70
 - Normal blood levels of, 267
 - With ticarcillin, 237
- Toenail
- Avulsion of, 35-36
 - Debridement of, 176-177
 - Discoloration of, 170
 - DSO in stratum corneum of, 171
 - Fungal infection of, 169
 - Infected ingrown, 34
 - Proximal white onychomycosis in, 171
 - Surgical removal of, 177-178
 - Treatment of fungal infections in, 171-172
 - White superficial onychomycosis (WSO), 171

- Total dystrophic onychomycosis, 171, 174
- Toxemia. *See also* Bacteremia; Septicemia.
 In clostridial myonecrosis, 45
 In infected vascular gangrene, 46
 In severely infected ulcerations, 116t, 126
 In necrotizing fasciitis, 43
 In synergistic necrotizing cellulitis, 44
- Toxic epidermal necrolysis (TEN), 38, 221
- Toxic megacolon, 218
- Toxic shock syndrome, 299
- Toxicities. *See* Antibiotic usage.
- Toxin titers and diagnosis of CDAD, 217
- Toxins
 From *Bacteroides*, 306
 From CA-MRSA, 328
 From *C. perfringens*, 302
 From *C. tetani*, 302
- Trade names of antibiotics, 347a-353a
- Transcutaneous oxygen, 127
- Transient bacteremia, 24
- Trauma
 Cellulitis due to, 10, 31
 Clostridial myonecrosis after, 45
 Madura foot after, 52
 Necrotizing fasciitis from, 43
 Onychomycosis vs. changes from, 173
 Puncture wound in marine, 93-94, 314, 319
 Pyomyositis and, 47
 Septic arthritis from, 77, 78
 Surgery as, 139
- Trauma, infections following
Acinetobacter in, 313
 Acute, 10
 Antibiotic prophylaxis for, 144
 Bite wounds and, 94-96
 Burn wounds and, 97-100
 Factors leading to, 83-85
 Infections following, 87-102
 Open fractures in, 100-101
 Organisms causing, 84t
 Pedal puncture wounds and, 87-94
 Surgical prophylaxis, 145-146
 Tissue gas due to, 42
 Wound care for, 85-87
 Wound closure after, 87
- Travel history
 Cutaneous larva migrans (CLM) and, 9, 52-53
 In diagnosis of lower extremity infections, 8-9
 Madura foot and, 51-52
 Pyomyositis and, 47
- Treponema*, 26
- Treponema pallidum*, 84t
- Trichomonas vaginalis*, 270
- Trichophyton mentagrophytes*
 Fungal infections due to, 157
 Tinea pedis due to, 157
 Vesicular tinea pedis due to, 159
 White superficial onychomycosis (WSO) due to, 171
- Trichophyton rubrum*
 Distal subungual onychomycosis (DSO) due to, 171
 Fungal infections due to, 157
 Moccasin tinea pedis due to, 158
 Proximal white onychomycosis due to, 171
 Tinea pedis due to, 157
- Trichophyton tonsurans*, 157
- Trimethoprim/ sulfamethoxazole (Bactrim, Septra), 285-286
 Against *Alcaligenes* and *Achromobacter*, 314
 Against *B. henselae*, 315
 Against *Citrobacter*, *Morganella*, *Serratia*, 308, 310, 313
 Dosage of, 346a
 Against *E. coli* and *Klebsiella*, 309, 310
 Against *E. corrodens*, 316
 Against *H. influenzae*, 316
 Against *M. marinum*, 319
 For marine puncture wounds, 93
 For mycobacteria infections, 319
 Against *P. mirabilis*, 311
 Against *P. multocida*, 316
 Against *S. aureus*, 297
 Against *S. maltophilia* and *B. cepacia*, 318
- Tropical regions, infections in, 47, 51
- Trough serum levels, 267, 268
- Tuberculosis (TB), osteomyelitis with extra-pulmonary, 73
- Type I reaction, 223
- U**
- Ulcerations. *See also* Mal perforans ulcerations
 Anaerobic gram-negative rods in, 306
 In arterial insufficiency, 126-127
 Classification of, 113-115

- Of injection site, 40
- In osteomyelitis, 75
- Risk of, 104
- Ulcerations, mildly infected, 121-122
- Ulcerations, moderate infected, 122-126
- Ulcerations, severely infected, 126
- Unasyn. *See* Ampicillin/ sulbactam.
- “Unholy triad”, 104
- University of Texas, San Antonio, 114
- Ureidopenicillins, 237
- Urinary tract infection (UTI)
 - Bacteremia due to, 24
 - From burn wound, 97
 - Carbenicillin for, 236
 - Doripenem for, 262
 - Hematogenous osteomyelitis due to, 73
 - Nosocomial fever with, 13
 - Septic arthritis and, 79
 - Trimethoprim/ sulfamethoxazole for, 285
- Urine, alternative therapy using, 86, 178
- Urosepsis, 9
- Urticaria, 223
- U.S. Army, 227

V

- Vancomycin (Vancocin), 273-275
 - For CDAD, 218
 - For cellulitis, 32
 - Against *Corynebacterium*, 303
 - For dead-space management, 70
 - For the empiric coverage of MRSA, 47
 - Against enterococci, 301
 - To fill “therapeutic holes”, 210
 - For injection site ulcerations, 41
 - Monitoring blood levels of, 222, 274
 - Nephrotoxicity and, 215, 265
 - Neutropenia due to, 219
 - For open fracture infections, 101
 - Ototoxicity due to, 214
 - For pyomyositis, 48
 - Red man syndrome due to, 221
 - Resistance to, 273, 296-297
 - And rifampin, 219
 - Against *S. aureus*, 297
 - For scalded skin syndrome, 38
 - For streptococcal infections, 299
 - For surgical prophylaxis, 149
- Vantin (cefepodoxime proxetil), 257
- Vascular insufficiency, osteomyelitis and, 55, 76-77

- Vascular studies, 77
- Vegetables, contamination of, 317
- Venography, 34
- Venous occlusions, acute, 10, 31
- Vertigo, 213
- Vesicles
 - In impetigo, 39
 - In vesicular tinea pedis, 159
- Vestibular impairment/ toxicity, 213, 265
- Vibrio*
 - Vs. *A. hydrophilia*, 314
 - In marine puncture wounds, 93
- Vibrio vulnificus*, 318
- Viral infections
 - And ampicillin, 233
 - With bacterial infections, 223
 - In diagnosis of lower extremity infections, 26
 - Septic arthritis from, 80
- Vision and diabetic foot infections, 109
- Vitamin K, 220
- Vitamin K metabolism disorders, 219, 220
- VRE (Vancomycin resistant *enterococcus*), 301
 - Daptomycin ineffective against, 278
 - Linezolid against, 276
 - Quinupristin/dalfopristin against, 275

W

- Wagner classification system of ulceration, 113-115
- Waldvogel, F.A., 56
- Warts, 156
- “Water loving” organisms, 93, 314
- Western blot techniques, 49
- Wet mount, 160-161
- White blood cell count (WBC)
 - And antibiotic usage, 219
 - In cellulitis, 31
 - And contiguous focus osteomyelitis, 75
 - In diagnosis of lower extremity infections, 15
 - In hematogenous osteomyelitis, 73
 - Hospitalization for elevated, 27, 28
 - In moderately to severely infected ulcerations, 123
 - In puncture wound infections, 91
 - In sepsis, 14
 - In septic arthritis, 79
- White blood cells in site infections, 4
- White superficial onychomycosis (WSO), 171, 172

Wood's lamp examination, 37, 304
World War II, 227, 324
Wound care
 Following burn trauma, 99-100
 Following pedal puncture wound
 trauma, 88-89
 For infections following trauma, 85-87
 For puncture wound infection, 92
Wound care, passive, 119
Wound closure
 Of burn wound, 99
 Infections caused by surgical, 136
 For infections following trauma, 87
 Of noninfected bite wound, 96
Wound healing
 Cellulitis with, 10
 Dead space infection in, 134
 Dead space management, 70
 Growth factors for active, 119
Wound prophylaxis, 144-145

X

Xanthomonas. *See Stenotrophomonas
Maltophilia*.

X-ray. *See Radiography*.

Y

Yeast infection. *See also Candida*.
 Due to antibiotic usage, 218

Z

Zaias, N., 158, 170
Zinacef (cefuroxime), 244t, 250
Zithromax. *See Azithromycin*, 197, 199,
 "Zone of inhibition", 197, 199, 334
Zoonosis 8, 50-51
Zoophilic organisms, 157
Zyvox (linezolid), 276-277, 337